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ABSTRACT 
Deletion 22q11.2 syndrome (22q11DS) is the most common 
microdeletion syndrome in man, with an incidence of approximately 
1:4000 live births (1); the major malformations include congenital heart 
defects such as truncus arteriosus (TA) and interrupted aortic arch type B 
(IAA-B), hypo/aplasia of the parathyroid and thymus glands, and 
craniofacial dysmorphism. Velo-cardio-facial (VCFS) and DiGeorge 
syndromes (DGS) are other diagnoses commonly made in affected 
individuals (1). The gene encoding the T-box transcription factor Tbx1, 
which is required for pharyngeal and cardiovascular development, has 
been identified as the gene haploinsufficient in mouse and human. 
We and others have identified a number of genes potentially targeted by 
Tbx1, but the mechanisms by which it can regulate the transcription of 
these genes and how it controls developmental pathways, are moslty 
unclear. 
One of the best studied molecular functions of Tbx1 is in heart 
development, where it is required to sustain proliferation of 
mesodermally-derived precursors of the second heart field (SHF), a 
cardiac progenitor cell population that contributes to the development of 
most of the heart, including the outflow tract and right ventricle. 
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To better understand how it works during embryonic development, we 
evaluated Tbx1-dosage dependent gene expression changes in vivo using 
a novel dosage gradient approach. Among genes sensitive to Tbx1 level, 
we found the one encoding the cardiogenic transcription factor Mef2c 
which is involved in cardiomyocyte differentiation. Interestingly, this 
gene was anti-correlated to Tbx1 dosage; in situ hybridization on mutant 
mouse embryos also corroborated quantitative expression data. These 
results suggest that Tbx1 may negatively regulate cardiac muscle cell 
differentiation through a mechanism involving Mef2c transcriptional 
repression; this would be consistent with recent data showing that loss of 
function of Tbx1 is associated with increased expression of differentiation 
markers of the myocardium.   
It has also been shown that Mef2c is a direct transcriptional target of 
Gata4 in the SHF, during mouse embryonic development (2); accordingly 
our in vitro data, suggest that Tbx1 could negatively regulate Mef2c 
expression, somehow interfering with Gata4-dependent Mef2c activation.    
Virtually all the mechanistic data obtained so far derive from murine 
models of 22q11DS; there is the need of a system to validate these data 
on human material. Since human Embryonic Stem cells can differentiate 
in vitro, into multiple somatic tissues, including cardiac progenitors, we 
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generated DiGeorge syndrome-specific Pluripotent Stem cells by 
reprogramming adult patient fibroblasts. Developing of this system as 
human model of the disease, will help us to investigate its underlying 
molecular mechanism on a cellular level. Tbx1 loss of function in mice, 
and, to a lesser extent, TBX1 haploinsufficency in DiGeorge syndrome 
patients, is associated with hypoplasia or aplasia of several organs and 
tissues; so it is possible that Tbx1 function in regulating the balance 
between proliferation and differentiation in the SHF, may also apply to 
other tissues where Tbx1 is expressed. Availability of DiGeorge 
syndrome-specific Pluripotent Stem cells, will help us to speculate 
whether that disregulation of the balance between proliferation and 
differentiation of different types of progenitor cells or stem cells, may be 
a basic pathogenic mechanism for the loss of function phenotype.  
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CHAPTER 1 
Introduction 
1.1 T-box genes 
Tbx1 belongs to the T-box gene family, which consists of at least 
seventeen different members in Mammals, organized into five distinct 
subfamilies based on phylogenetic analyses and presumed gene 
duplication events during evolution. T-box genes encode a group of 
phylogenetically conserved transcription factors, defined by a common 
DNA binding domain, the T-box sequence, the T-site or T-box binding 
element (TBE), that was was first defined as the sequence with the 
highest affinity for Brachyury (3). Brachyury binds this palindromic 
sequence as a dimer (4), with each monomer of Brachyury binding half of 
the sequence, or T-half site (5 -AGGTGTGAAATT-3 ). Extensive studies 
have demonstrated that all T-box proteins tested are capable of binding 
the T-half site as monomers (4-10), although some have different optimal 
target sequences (11, 12). Comparisons between T-box proteins have 
shown reference for different synthetic combinations of T-half sites in 
varying orientations, numbers, and spacing (9, 13), which may help to 
create promoter specificity for target genes. 
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As well as binding DNA, T-box genes have been shown to regulate 
transcription. Activation domains have been mapped to the C-terminal 
domains of several T-box proteins (10, 14, 15). T-box proteins can also 
repress transcription, as has been shown for Tbx2, Tbx3 and Tbx20 (12, 
16-19). Some T-box genes contain both activation and repression 
domains in their C-terminal domains (10, 14) and Tbx2 has been reported 
to act in either fashion, depending on promoter context (8). Although 
some T-box gene targets appear to be regulated by T-box proteins alone 
(20), there is a growing body of work demonstrating that target genes are 
controlled in combination with other transcription factors. Cooperative 
binding of promoters and synergistic upregulation of target gene 
expression is seen with T-box factors and homeodomain (7, 10), GATA 
zinc finger (10, 21, 22), and LIM domain proteins (23). Frequently, these 
interactions enhance target gene activation, and probably contribute to 
promoter specificity. Some of these interactions can be generalized to 
transcription factor subfamilies while others are exquisitely specific; 
Tbx20, for example, interacts with GATA5 but not the related 
transcription factor GATA4 (10). In an even more extreme case of 
specificity, LMP4 binds both of the most closely related vertebrate T-box 
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proteins, Tbx4 and Tbx5, but interacts with each via a different LIM 
domain repeat (23). 
1.2 T-box transcription factors and human disorders 
Members of the evolutionarily conserved T-box family of transcription 
factors are important players in developmental processes that include 
mesoderm formation and patterning and organogenesis both in 
vertebrates and invertebrates. The importance of T-box genes for human 
development is illustrated by the association between mutations in several 
of the seventeen human family members and congenital errors of 
morphogenesis that include cardiac, craniofacial, and limb malformations 
(24, 25). 
Ulnar-mammary syndrome (UMS, OMIM 181450) is caused by 
mutations in TBX3, (26-28). It affects the ulnar ray of the limb with 
phenotypes ranging from hypoplasia of the terminal phalanx of the fifth 
digit, to the complete absence of forearm and hand (28). Patients with 
UMS also have abnormal development of breasts, teeth and genitalia (29, 
30). Male patients typically have delayed onset of puberty (31). TBX3 is 
expressed in a wide range of tissues including those where developmental 
abnormalities occur in UMS (27, 32, 33). There does appear to be a 
correlation between TBX3 mutations and UMS symptoms, suggesting that 
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haploinsufficiency of TBX3 causes UMS. TBX3 has a role in specification 
of posterior limb mesoderm and in setting up the dorso/ventral limb axis. 
In some cases of UMS, posterior structures are lost or duplicated, and in 
others the ventral surface of posterior digits becomes dorsalized (28). 
Breast, tooth and genital development all rely on inductive interactions 
between epithelial tissue and underlying mesenchyme (34-36) and TBX3 
may have a common role in these developmental processes. 
Holt–Oram syndrome (HOS, OMIM 142900) is an autosomal dominant 
disorder affecting 1 in 100000 live births. It is completely penetrant with 
a highly variable expression and causes both cardiac and skeletal 
congenital abnormalities. The skeletal abnormalities affect the forelimb, 
and include clinodactyly, limited supination, sloping shoulders and 
phocomelia. They affect the radial ray and are bilateral and asymmetrical, 
affecting the left side more severely than the right. Defects observed in 
the heart affect the conduction system, atrial and ventricular septation and 
tetralogy of Fallot. A high proportion of patients have an absence of the 
pectoralis major and an ocular defect (37). Mutations in TBX5 have been 
identified in both familial and sporadic cases of HOS (38-43). The 
majority of mutations in TBX5 are null alleles that cause the HOS 
phenotype by haploinsufficiency; they cause both severe cardiac and  
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skeletal phenotypes. A mouse model of Holt–Oram syndrome has been 
made (5); heterozygous Tbx5del/+ mice show both cardiac and forelimb 
defects, having enlarged hearts with atrial septal defects and conduction 
defects as well as hypoplastic falciformis bones in the wrist and elongated 
phalanges in the first digit of the forelimb.  
Tbx19, also known as Tpit, was identified as required for expression of 
pro-opiomelanocortin (POMC) in the corticotroph and melanotroph 
pituitary lineages (7). Expression is restricted to the ventral aspects of the 
anterior pituitary and the ventral diencephalon (7, 44). In humans the 
absence of pituitary POMC leads to a lack of adrenocorticotrophin 
(ACTH) resulting in adrenal insufficiency (OMIM 201400). TBX19 (45) 
was screened in patients with this phenotype and seven different 
mutations were identified (7, 46). Isolated ACTH deficiency is 
transmitted recessively; in all cases, except for one compound 
heterozygote, the patients were homozygous for a TBX19 mutation while 
their unaffected parents were heterozygous carriers (46). The missense 
mutations identified had severely reduced ability to bind their DNA target 
and activate transcription while the other mutations generated 
prematurely terminated transcripts. This suggests that the TBX19 
mutations described were loss-of-function alleles. Tbx19 activates the 
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POMC promoter synergistically with the homeodomain protein Pitx1 (7); 
this activation requires both transcription factors to be bound to the DNA. 
Ectopic expression of Tbx19 in cells expressing high levels of Pitx1 is 
sufficient to activate POMC, suggesting that it may act as a signal to 
initiate POMC cell differentiation (7). Tpit-deficient mice model isolated 
ACTH deficiency (46) and should facilitate understanding of 
differentiation of the pituitary corticotroph lineage. 
Cleft palate affects 1 in 1500 births and is caused by failure of the paired 
palatal shelves to make contact and form the midline seam which later 
disappears, allowing the palate to become confluent. Cleft palate causes 
problems with feeding, speech, hearing, dental and also psychological 
development, and requires corrective surgery. It is usually sporadic and 
involves both genetic and environmental factors (47, 48). However, cleft 
palate with ankyloglossia (CPX, OMIM 303400) is a semi-dominant X-
linked condition mapping to Xq21 in which environmental factors play 
little part (49-52). TBX22 was identified on Xq21 during the human 
genome project (53, 54). It maps to the CPX critical region and is 
expressed at the correct time and in the appropriate tissue for 
palatogenesis (55-57). Screening of individuals with CPX has identified 
eight point mutations in TBX22 including splice site, missense and 
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nonsense mutations (55, 58). These segregate with the disorder in their 
respective families confirming TBX22 as the causative gene for CPX.  
Mutations in the human TBX4 gene underlie Small Patella Syndrome 
(SPS) also referred to as “Scott-Taor syndrome”, “ischio-pubicpatellar 
syndrome”, “coxo-podo patellar syndrome” or “ischiopatellar dysplasia”, 
which is a rare autosomal-dominant disorder affecting skeletal structures 
of the lower limb and the pelvis (59-63). Essential features for the clinical 
diagnosis of SPS are patellar aplasia or hypoplasia, associated with 
absent, delayed, or irregular ossification of the ischiopubic junctions 
and/or the infra-acetabular axe-cut notches (64). In addition, femur and 
foot anomalies and pes planus, may accompany SPS. Craniofacial 
dysmorphisms have been described in reports of four sporadic individuals 
with SPS and one familial case of SPS including micrognathia and/or 
cleft palate (64-68). The SPS phenotype suggests that human TBX4 
mutations do not affect early steps in limb development, such as limb-bud 
initiation, but do have a profound effect at later stages. The late effect of 
TBX4 mutations is manifested by patellar aplasia/hypoplasia and 
anomalies of the posterior structures of the foot, such as short fourth and 
fifth rays. Completion of ischiopubic formation is another very late 
process in human development, that is disrupted in individuals with SPS 
 21
(69). 
Laush et al. (70) identified two unrelated individuals affected by Cousin 
syndrome, a complex cranial, cervical, auricular, and skeletal 
malformation syndrome with scapular and pelvic hypoplasia (Cousin 
syndrome) that recapitulates the dysmorphic phenotype seen in the 
Tbx15-deficient mice, droopy ear. Droopy ear exhibits a complex 
craniofacial malformation including small, widely spaced eyes with short 
palpebral fissures, a broad nasal area, a shortened skull held in an 
elevated position, misshapen and rotated external ears, and an abnormal 
coat-color patterning (71, 72). The skeletal phenotype of Tbx15-
inactivated mice includes small overall size, hypoplastic scapulae, 
moderate shortening of several long bones, and a dysmorphogenesis of 
cranial bones and cervical vertebrae, including vertical displacement of 
the supraoccipital bone, a small basiooccipital bone, a small foramen 
magnum, and changes in the shape of the squamosum and of the first and 
second vertebrae (73, 74). Both affected individuals shared an identical 
phenotype consisting of short stature and macrocephaly; their dysmorphic 
features included frontal bossing, narrow palpebral fissures with deep set 
globes and hypertelorism, strabismus, low-set ears with posterior rotation 
and dysplasia of the conchae, narrow auditory canals and hypoacusis, a 
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short neck with redundant skinfolds, and a low hairline. The main 
radiographic features were hypoplastic scapulae and iliac bones, short 
femurs, humeroradial synostosis, and moderate brachydactyly. Both 
patients were homozygous for genomic TBX15 mutations that resulted in 
truncation of the protein and addition of a stretch of missense amino 
acids. Although the mutant proteins had an intact T-box and were able to 
bind to their target DNA sequence in vitro, the missense amino acid 
sequence directed them to early degradation, and cellular levels were 
markedly reduced, suggesting that Cousin syndrome is caused by TBX15 
insufficiency and is thus the human counterpart of the droopy ear mouse. 
TBX20 is an ancient member of the T-box transcription factor family, 
related to TBX1. In mice, it is expressed in cardiac progenitor cells, as 
well as in the developing myocardium and endothelial cells associated 
with endocardial cushions, the precursor structures for the cardiac valves 
and the atrioventricular septum (10, 18). Loss of Tbx20 in mice is 
catastrophic for heart development; homozygous mutants show a 
rudimentary heart that is poorly proliferative and lacks chamber 
myocardium (18, 19, 75). Tbx20 also has later functions in 
atrioventricular valve development: adult heterozygous Tbx20-knockout 
mice show mild atrial septal abnormalities, including an increased 
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prevalence of patent foramen ovale (PFO) and aneurismal atrial septum 
primum, as well as mild dilated cardiomyopathy (DCM) and a genetic 
predisposition to frank ASD (18). The essential roles of Tbx20 in heart 
development and adult heart function in mice, raised the possibility that 
mutations in human contribute to congenital heart disease (CHD), 
structural malformations of the heart which are extremely common, 
present in nearly 1 in 100 live births and 1 in 10 stillborns. Kirk et al., in 
fact, identified TBX20 mutations in two white CHD-affected families; 
both mutations occurred in the T-box domain affecting the  protein DNA-
binding ability and were associated with a complex spectrum of 
developmental and functional abnormalities, including defects in 
septation, valvulogenesis, and chamber growth as well as 
cardiomyopathy, so establishing the first link between TBX20 mutation 
and human disease (76). 
Finally TBX2 maps to 17q23 region which is frequently altered in ovarian 
carcinomas (77), and is amplified in about 20% of breast cancers (78). 
TBX2 is amplified in some breast cancer cell lines, with about 4.5% of 
sporadic breast cancers having a dosage increase equivalent to one extra 
copy of the TBX2 allele. A screen designed to identify immortalizing 
genes in breast cancer showed that TBX2 affects the p53 tumour 
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suppressor pathway by repressing the cdkn2a (p19ARF) promoter (79),   
implying a role for this T-box gene in cancer.  
1.3 TBX1 and Del22q11.2/DiGeorge syndrome 
TBX1 is the major candidate gene for the Del22q11.2 syndrome; 
del22q11.2 is an interstitial deletion of chromosome 22 associated with a 
characteristic phenotype clinically recognizable as DiGeorge syndrome, 
velocardiofacial syndrome or conotruncal anomaly face, which are 
collectively referred to as 22q11.2 deletion syndromes (22q11.2DS) 
which is estimated to be the most common microdeletion syndrome in 
humans, affecting about 1 in 4000 live births. Microdeletion syndromes 
are genetic disorders caused by the loss of a small chromosomal segment, 
usually spanning multiple genes, but too small to be detected by standard 
cytogenetic analysis. There are actually several versions of del22q11.2 
and the most common version eliminates 3 Mb of genomic DNA, 
including approximately 40 genes; smaller deletions are associated with 
essentially identical phenotypes. 
Long-range DNA mapping analysis, molecular cytogenetics, and, more 
recently, genome sequencing have identified stretches of DNA sequences 
repeated multiple times along the chromosomal band 22q11.2. Some of 
these sequences, referred to as low copy repeats (LCRs), localize at or 
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near the break points of del22q11. Therefore, LCRs are thought to 
provide the substrate for aberrant DNA recombination leading to 
chromosomal deletions. LCRs have been found in all the human 
chromosomes, and they have been implicated in a number of 
chromosomal rearrangements, including deletions, duplications, and 
translocations. Thus, the genomic architecture of 22q11 explains the 
homogeneity of the deletion across patients and perhaps also the high 
incidence of this rearrangement. It has been shown, in fact, that del22q11 
originates predominantly through aberrant interchromosomal exchange at 
LCR sites (80-85).  
Patients who carry del22q11 seek treatment with a complex clinical 
picture including the DiGeorge, velocardiofacial, and conotruncal 
anomaly face phenotypes. Clinical findings can be classified in three 
categories: (1) pharyngeal phenotype, related to developmental defects of 
the embryonic pharyngeal apparatus; (2) neurobehavioral phenotype, 
mostly learning disabilities and psychiatric disorders; and (3) a 
heterogeneous group of clinical signs or developmental defects such as 
kidney abnormalities, non craniofacial skeletal defects, and vascular 
abnormalities. Most patients have clinical signs from at least two of these 
three categories of phenotypes.  
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The embryonic pharyngeal system is a transient, vertebrate-specific 
structure comprising alternating bulges (arches) and indentations 
(pouches and clefts) that develops sequentially along the body axis in a 
head-to-tail direction. The pharyngeal arches are overlaid by surface 
ectoderm and lined by endoderm, which we refer to together as the 
pharyngeal epithelia. Between the epithelial layers of the pharyngeal 
apparatus, there is mesenchyme of mesodermal origin that is later 
infiltrated by ectomesenchyme of neural crest origin. The pharyngeal 
system contributes, among other organs and structures, to the formation 
and/or morphogenesis of the thymus, thyroid, parathyroids, maxilla, 
mandible, aortic arch, cardiac outflow tract, external and middle ear. 
Many birth defects, including a large fraction of congenital heart disease 
cases, derive from developmental problems of the pharyngeal system; so 
the research interest in the del22q11.2 syndrome is driven not only by the 
obvious clinical significance of the disease, but also by a broader 
biological importance: this syndrome is the most typical developmental 
defect of the embryonic pharyngeal system. The pharyngeal phenotype 
comprises in fact, physical signs derived from developmental 
abnormalities of the pharyngeal arches and pouches: specifically, 
craniofacial (including external and middle ear) abnormalities, thymus, 
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parathyroid and, in some cases, thyroid hypoplasia or aplasia (86, 87), 
aortic arch and cardiac outflow tract abnormalities (interrupted aortic arch 
type B, abnormal origin of the right subclavian artery, right sided aortic 
arch, tetralogy of Fallot), ventricular and atrial septal defects (VSD, 
ASD).                                          
Investigators have used the power of mouse genetics to determine which 
of the many genes deleted in patients could be required for the 
development of the pharyngeal apparatus. The first genetic model of 
del22q11DS was a mouse mutant with an engineered deletion of most of 
the mouse genomic region homologous to the region deleted in del22q11 
patients (88). These mice, carrying a heterozygous deletion named Df1/+, 
have aortic arch defects and parathyroid, thymic, and neurobehavioral 
abnormalities, reminiscent of those found in human patients (88-90). 
Additional targeted mutations of the mouse genome allowed investigators 
to attribute most of these phenotypic findings to haploinsufficiency (a 
situation in which a single copy of the normal gene is insufficient to 
assure normal function) of a single gene, precisely Tbx1 (91-93). To 
determine whether TBX1 haploinsufficiency was the main cause of the 
22q11.2DS phenotype also in humans, investigators performed 
mutational analysis in patients with a 22q11.2DS-like phenotype but 
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without the chromosomal deletion. An initial report (93) analyzed the 
TBX1 coding region in 100 patients but did not find mutations. 
Subsequently, Gong et al. (94) tested 105 patients and found several rare 
variants, mostly located in exon 9 coding for the C-terminal region of the 
TBX1 protein. Unfortunately, the authors could not definitively link these 
variants to the disease status. Later, Yagi et al. (95) reported a family 
segregating frame-shift mutation (1223delC) located 51 bp upstream of 
the one reported by Gong et al (94). Family members carrying this 
mutation presented with a variable but characteristic 22q11.2DS 
phenotype ranging from severe to very mild. This is the strongest 
evidence available to date that links TBX1 mutations to the del22q11.2DS 
phenotype. Yagi et al. (95) also identified two additional mutations in 
patients with typical phenotypes. These were de novo missense 
mutations, F148Y and G310S; the first was located in the highly 
conserved T-box domain, and the other was located immediately 
downstream to the T-box domain, also in a highly conserved region. The 
effect of all of the reported mutations on protein function is still 
unknown. The mutation affecting the T-box domain is likely to impair 
DNA binding activity of the TBX1 protein, but the effect of the other 
mutations are less predictable as we do not have a catalog of functional 
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domains of the protein. The identification of functional domains is, of 
course, an important subject for future research.  
1.4 Tbx1 roles during mouse embryonic development 
DiGeorge syndrome phenotype, both in mice and humans, suggests 
critical roles for Tbx1 during pharyngeal system development; Tbx1 
expression pattern is highly dynamic during development and is mainly 
localized in the head mesenchyme, pharyngeal endoderm (PE), core 
mesenchyme of the cranial pharyngeal arches, outflow tract of the heart, 
mesenchyme surrounding the dorsal aortae, otocyst and sclerotome.  
Pharyngeal arches develop one after the other, in a cranial–caudal order, 
and surround the embryonic pharynx, which is lined by the PE. The PE of 
the pouches contributes to the development of the parathyroids and 
thymus, and the ventral PE contributes to the development of the thyroid. 
The first pharyngeal arches form the maxilla and mandible; the second 
form the hyoid bone. Tbx1-/- have severe developmental defects of the 
pharyngeal apparatus: the characteristic segmented arrangement is lost, 
the embryonic pharynx is severely hypoplastic and lacks pouches, hence 
presenting a tube-like morphology. The first pharyngeal arch is 
abnormally patterned (96), the second is very hypoplastic, and the third, 
fourth and sixth are not identifiable (91, 97). Pharyngeal arch arteries 
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(PAAs) run inside the pharyngeal arches, surrounded by mesenchymal 
cells, most of neural crest and some of paraxial mesoderm origin. Tbx1 
haploinsufficiency causes early growth and remodeling defects of the 
fourth PAAs, first evident at embryonic day (E) 10.5. The caudal PAAs 
(third, fourth and sixth) form sequentially as symmetric vessels 
connecting the aortic sac with the dorsal aortae. From ~E11.5, the PAAs 
undergo a major, asymmetric remodeling that leads to the mature aortic 
arch and great vessel patterning (98). In particular, the left fourth PAA 
contributes to the section of the mature aortic arch between the origins of 
the left common carotid artery and the left subclavian artery. 
Developmental failure of the left fourth PAA causes interruption of the 
aortic arch type B (IAA-B). The right fourth PAA provides the 
connection of the right subclavian artery with the innominate artery. 
Developmental failure of the right fourth PAA causes aberrant origin of 
the right subclavian artery, most commonly from the descending aorta, 
via a retroesophageal vessel. Thus, all pharyngeal segments are affected, 
but the caudal segments are more severely affected. This is consistent 
with dynamic expression of Tbx1 in the pharyngeal endoderm, which 
tends to increase in intensity along cranial–caudal and medial–lateral 
directions. These are also the directions of growth/extension of the 
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pharyngeal endoderm during E9 to 10.5 in mice (99, 100).  Expression of 
Tbx1 in other pharyngeal tissues (core mesoderm and head mesenchyme) 
is less dynamic in nature and less suggestive of a role in pharyngeal 
system growth and segmentation. 
Because the pharyngeal pouches do not form in Tbx1-/- mice, it is possible 
that one of the functions of Tbx1, perhaps the earliest during 
development, is to initiate and maintain the invagination of the endoderm, 
cell autonomously. The invagination then extends to form the pharyngeal 
pouch; in principle, this mechanism would be similar to those proposed 
for the formation of other ‘tubular’ organs such as the lung (101). The 
cranial–caudal ‘wave’ of Tbx1 expression may drive the order in which 
the pouches form. It would be very interesting to establish how this 
process is regulated upstream of Tbx1. Perhaps the notochord could 
provide the appropriate signals. Indeed, Sonic hedgehog (Shh), which is 
highly expressed in the notochord, has been shown to activate Tbx1 
expression in chick, while in Shh-/- mice, Tbx1 is downregulated (102). 
However, Shh-/- mice have less severe defects of the caudal pharyngeal 
arches and pouches than Tbx1-/- mice, suggesting that the regulation of 
Tbx1 by Shh may be more important for the most-cranial pharyngeal 
segments. Initial migration of cranial neural crest cells, their proliferation 
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and survival appear normal in Tbx1-/- embryos; however, migration 
streams, especially the caudal ones, become abnormal and disordered as 
cells enter the pharyngeal area, and cranial nerves, derived from neural 
crest cells, are misdirected (97). We speculated that normally the 
endodermal pouches provide guidance to the migrating neural crest cell 
streams; in the absence of pouches, migration is affected and pharyngeal 
arches do not develop. Tbx1 is expressed in the endoderm that surrounds 
the 4th PAAs but not in the arteries themselves. Therefore, it has been 
hypothesized that Tbx1 affects the growth of the artery through a non-
cell-autonomous mechanism involving a diffusible signal triggered in 
endodermal cells of the pouches and directed toward the artery (97); so a 
key question is how Tbx1 expression in the pharyngeal endoderm can 
trigger molecular signals to the underlying mesenchyme to support vessel 
growth. FGF signaling has been shown to interact with other T-box genes 
and therefore it is possible that FGF molecules may mediate the role of 
Tbx1 in fourth PAA growth. The Fgf8 gene expression pattern overlaps 
with that of Tbx1 in the pharyngeal endoderm around the time when the 
fourth PAA hypoplasia becomes apparent; in addition Fgf8 expression in 
the pharyngeal endoderm of Tbx1 null mutant embryos is lost, while the 
other expression domains are maintained (103). Loss of Fgf8 in the 
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pharyngeal endoderm may be due to gene downregulation or lack of 
development/survival of endodermal cells expressing Fgf8; several 
endodermal markers (Shh, Nkx2-5 and Pax9), are robustly expressed in 
homozygous mutants. In addition, using our Tbx1-lacZ-knock in allele, 
we demonstrated beta-gal activity in the endoderm of Tbx1–/– embryos, 
indicating that Tbx1 function is not required for the contribution of Tbx1-
expressing cells to the endoderm (103). Overall, these data suggest that 
the endoderm of Tbx1–/– embryos is properly specified. The gene 
expression data suggest that Fgf8 may interact with Tbx1 in the 
pharyngeal endoderm and be a mediator of the cell non-autonomous role 
of Tbx1 in fourth pharyngeal arch artery development. Accordingly with 
this hypothsis Tbx1+/–;Fgf8+/– mice presented with high penetrance of arch 
defects, significantly higher than that found in Tbx1+/–;Fgf8+/+ mutants; 
interestingly, the type of defects observed was not affected by Fgf8 
mutation, all defects were attributable to a failure of the fourth PAA 
development. In addition, the penetrance of fourth PAA abnormalities 
caused by Tbx1 haploinsufficiency at E10.5 is much higher than the 
penetrance of aortic arch defects at E18.5, indicating a Tbx1- Fgf8 genetic 
interaction during the early phases of fourth PAA development, 
consistent with the time of Fgf8 and Tbx1 expression overlap in the 
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pharyngeal endoderm. Double heterozygous mutants also showed an 
higher penetrance of thymic hypoplasia and/or lobe asymmetry mutants; 
and because the thymus primordia develop from the third pharyngeal 
pouch where both Tbx1 and Fgf8 are expressed, it is likely that the 
thymic phenotype in double heterozygous mutants is also a sign of Tbx1-
Fgf8 interaction in the pharyngeal endoderm. 
Recently we showed that also early thyroid development requires a Tbx1-
Fgf8 pathway (104); the thyroid is an endocrine gland that secretes two 
types of hormones, thyroxin and calcitonin, which are produced by two 
distinct cell types, the thyroid follicular cells (TFC) and the parafollicular 
or C-cells, respectively. These two cell types derive from distinct regions 
of the pharyngeal endoderm, specifically the ventral pharyngeal 
endoderm provides the TFC progenitors, while the endoderm of the 4th 
pharyngeal pouches provides the C-cell progenitors. The TFC progenitor 
population constitutes the early primordium at approximately E8.5, when 
it appears as thickened epithelium on the ventral-medial wall of the 
pharynx, just caudal to the 1st pharyngeal arch. The early primordium 
then grows without further cell proliferation (105) presumably by 
recruiting cells from the adjacent endoderm, and forms a pit by 
invaginating into the pharyngeal mesenchyme. Between E11.5 and E13.5, 
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the primordium grows deeper into the mesenchyme, detaches from the 
pharyngeal endoderm, and begins to expand laterally. Later, the thyroid 
primordium reaches the trachea where it fuses with the 4th pouch-derived 
ultimobranchial bodies, which provide the C-cells of the mature organ. At 
around E15–E16, the thyroid gland acquires its final shape, i.e. two lobes 
connected by a narrow isthmus. From this stage, the organ grows and 
begins to express functional markers such as thyroglobulin (tg), 
thyroperoxidase (TPO) and Tshr (106). The signals that induce the initial 
events of specification and migration of thyroid precursor cells are still 
unknown. It has been postulated that the invagination process involves 
epithelial–mesenchyme transition. Congenital hypothyroidism has been 
reported in several cases of 22q11DS patients, although it is not a 
common feature of the syndrome (107). Tbx1 mouse mutants present with 
a small thyroid, suggesting that the gene contributes, directly or 
indirectly, to thyroid development (108). The thyroid primordium and the 
ultimobranchial bodies, which derive from the 4th pharyngeal pouches, 
fuse at E13 and contribute to the mature gland. Tbx1 null mutants do not 
have 4th pharyngeal pouches, thus thyroid hypoplasia in these mutants 
could be explained in part by the absence of the ultimobranchial bodies-
derived component of the mature organ (108). However, loss of Tbx1 
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already affects thyroid development at E11.5 (105), indicating that loss of 
the 4th pharyngeal pouch is insufficient to explain the phenotype. It has 
been suggested that the bilobation defect of the thyroid in Tbx1-null mice 
could be due to failure of the thyroid primordium to establish a contact 
with the aortic sac, which normally occurs at around E11.5–12 (105), 
possibly through failed signaling between endothelial cells and 
primordium. So Tbx1 seems to have a much earlier role in thyroid size, as 
the primordium is smaller from E9. In order to exclude a role of Tbx1 in 
the endothelium adjacent to the primordium, we ablated the gene in 
endothelial cells using the Tie2-Cre driver, founding that the thyroid of 
Tie2-Cre; Tbx1flox/− embryos at E18.5 was of normal size. The role of 
Tbx1 in the thyroid appears to be limited to regulating the number of cells 
of the primordium and does not appear to be involved in differentiation of 
thyroid precursors, as the expression of thyroid specific markers was not 
affected in Tbx1 mutants. In addition, the mutant thyroid primordium 
does not regress and is still capable of growing, although it will never 
reach the normal, final size. This suggests that the primary defect is at or 
precedes primordium formation. Conditional ablation of Tbx1 in the 
mesoderm is sufficient to recapitulate the null thyroid phenotype, thus 
indicating that the mesoderm plays a critical role in signaling to the 
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developing thyroid or their progenitors. We previously showed that loss 
of Tbx1 in the mesoderm is associated with reduced cell proliferation in 
the pharyngeal endoderm of early embryos, thus providing a possible 
explanation as to why the primordium is small. Conditional ablation of 
Fgf8 in Tbx1-expressing cells causes severe early and late thyroid 
hypoplasia, similarly to Tbx1 ablation. Conversely, forced expression of 
Fgf8 in the Tbx1 expression domain, partially rescues the early and late 
Tbx1−/− thyroid phenotype. Endogenous Fgf8 expression in the mesoderm 
near the thyroid primordium is only detectable in early embryogenesis 
(up to approx. E9.0), consistent with the early appearance of the Tbx1 
mutant phenotype. Totally these data support a Tbx1-dependent role for 
Fgf8 in thyroid development, and they are consistent with a report 
showing a critical role of this gene in zebrafish thyroid development 
(109). In addition, Olivieri et al. showed that pharyngeal mesoderm 
(including the cardiogenic mesoderm of the secondary heart field) 
supports thyroid development, thus providing a possible explanation for 
the frequent association between congenital heart disease and thyroid 
dysmorphogenesis (110). 
Chromosome 22q11.2 deletion is one of the most common genetic causes 
of cardiac outflow tract (OFT) defects too. The OFT forms as a simple 
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vascular conduit that connects the embryonic right ventricle to the aortic 
sac, which is the site of confluence of the pharyngeal arch arteries. The 
embryonic OFT, which is divided into conal (proximal to the heart) and 
truncal (distal) segments, is soon lined by myocardial cells derived from 
migrating mesodermal cells. The myocardial layer of the embryonic OFT 
contracts and functions as a primitive valve. Septation separates the OFT 
into two channels, which direct the blood flow towards the aortic 
(systemic) and pulmonary circulation, and divides the primitive truncal 
valve into the aortic and pulmonary valves. Whereas the heart 
myocardium derives from lateral plate mesoderm precursors (the primary 
heart field), the OFT myocardium derives from the splanchnic mesoderm 
located caudal to the pharynx, the second heart field (SHF): in particular, 
the first lineage contributes to the left ventricle, atria, inflow region and 
partly to the right ventricle; the second one, which is characterized by the 
expression of the LIM-homeodomain protein Isl1, is thought to contribute 
mainly to the right ventricle and the outflow tract, but also the atria and 
the inflow region (111-114). The molecular mechanisms underlying 
induction and differentiation of myocardial precursors in the SHF are 
hypothesized to be similar to those of the primary heart field (113), but 
the genetics of SHF function and the phenotypic consequences of SHF 
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malfunction are uncertain. Neural crest-derived cells are also required for 
OFT septation and make up most of the aorto-pulmonary (AP) septum, a 
structure that originates from the dorsal wall of the aortic (115-118). 
Severe developmental defects of the OFT are tolerated during 
embryogenesis, provided that they do not compromise patency, but are 
lethal in post-natal life, when the pulmonary circulation is required for 
blood oxygenation. OFT developmental defects account for a high 
proportion of congenital heart disease cases and, consequently, are an 
important cause of morbidity and mortality in children. 
Tbx1–/– animals have severe OFT abnormalities including complete lack 
of septation and abnormal alignment of the truncus arteriosus with the 
ventricles (91, 97). These abnormalities seem to be because of a specific 
role of Tbx1 in OFT development and not secondary to the severe defects 
of the pharyngeal apparatus associated with Tbx1 loss of function.  
Tbx1 is expressed in progenitors as well as in differentiated, resident 
myocytes and endothelial cells of the OFT. However, conditional deletion 
experiments indicate that Tbx1 function is not required in myocardial or 
endothelial cells; instead, cell fate mapping experiments indicate that 
Tbx1 regulates, but is not required for contribution of myocytes, and 
possibly other cell types, to the OFT. Most probably, Tbx1 does not 
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directly regulate cell proliferation of progenitor cells because in chimeras, 
Tbx1–/– cells do not have a proliferative disadvantage in the SHF. Thus, 
the Tbx1 role in regulating cell contribution to the OFT is probably cell 
non-autonomous. Fgf10 is a candidate mediator of this function because 
its expression in the SHF is abolished in Tbx1–/– and Tbx1 can directly 
activate, through a conserved TBE, the Fgf10 promoter in a tissue culture 
assay. Interestingly though, Fgf10–/– animals do not have OFT defects, 
raising the question as to whether Tbx1 also activates other Fgf genes or 
other extracellular signaling systems critical for OFT morphogenesis. 
Alternatively, Fgf10–/– animals may not have OFT defects because other 
Fgf genes compensate for the loss of Fgf10, as proposed by Kelly and 
Buckingham (119). Tbx1 has an additional role in OFT morphogenesis; it 
is, in fact, required in cells expressing Nkx2.5, one of the first splanchnic 
mesodermal cell marker, for the formation of the aorto-pulmonary 
septum, which divides the aorta from the main pulmonary artery (120).  
During mouse embryonic development, Tbx1 is also required for inner 
ear morphogenesis; the inner ear derives from the otic placode, initially 
recognized as a thickened ectodermal patch near the hindbrain at E8 in 
mice. The otic placode undergoes invagination and becomes the otic pit, 
which in turn enlarges and closes off from the ectoderm to form the 
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otocyst by E9.5 (121). Cells in the otocyst undergo a series of cell fate 
specification events and differentiate into the various types of cells that 
populate the inner ear structures (122). From E9.5 to E12, neuronal 
precursors delaminate from a specific region of the otic epithelium, the 
neurogenic region, to contribute to the cochleo-vestibular ganglion 
(CVG). The neurogenic region is defined by activation of the Delta-
Notch pathway and expression of proneural genes encoding bHLH 
transcription factors, including Neurogenin1 (Ngn1) and NeuroD (123, 
124). By E12, the delamination process is complete, and the otocyst 
exhibits recognizable primordial structures of sensory organs and 
endolymphatic duct (121). During otocyst development, Tbx1 is 
expressed in a subregion of the otic epithelium and in the periotic 
mesenchyme (125, 126): it has been shown that both expression domains 
are essential for inner ear morphogenesis. Tbx1 continues to be expressed 
in the primordial of the sensory organs and expression is evident until at 
least E13.5 (126). In Tbx1-/- animals, the otocyst is small and the sensory 
organs do not form (125-127); in addition, the neurogenic region  of the 
otic epithelium is expanded (125) and the endolymphatic duct appears to 
be enlarged (127). We previously (128) showed that Tbx1 is required for 
localization, expansion and fate determination of a cell population that 
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forms most of the otocyst, excluding the neurogenic and the 
endolymphatic duct territories; delayed ablation of Tbx1 partially rescued  
this cell population, but strongly reduced its proliferation in the otocyst. 
In addition, even if this Tbx1-dependent cell population does not 
normally contributes substantially to the cochleo-vestibular ganglion, 
timed deletion of Tbx1 results in the expansion of the Delta-like1-Notch1 
activation domain, and in change of fate of at least some of Tbx1- 
expressing cells towards a neurogenic fate. The molecular mechanisms 
that set the border of the neurogenic region in the otocyst are unknown. 
Delta-Notch signalling plays a role in determining the neurogenic versus 
non-neurogenic fate in other tissue contexts. Delta is positively regulated 
by proneural genes Ngn1 and NeuroD (129), and in turn activates Notch 
in neighboring cells; aNotch finally suppresses proneural gene expression 
in those cells. Expression of Dll1, a Notch ligand, and the cleaved form 
of Notch1, are found at or near the neurogenic border region, suggesting 
that the Delta-aNotch signalling could play a role in setting or 
maintaining the border. Tbx1 mutation is associated with a considerable 
expansion of the Dll1-aNotch domain, suggesting that it functions 
upstream of a possible Notch-mediated mechanism for selecting cells 
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undergoing neurogenic fate: so Tbx1 may suppress Ngn1 and/or Dll1 
expression. 
1.5 The emerging Tbx1 genetic pathway 
Yamagishi and colleagues (130) identified a single cis-element upstream 
of Tbx1 that recognized winged helix/forkhead box (Fox)-containing 
transcription factors (131, 132) and is essential for regulation of Tbx1 
transcription in the pharyngeal endoderm and head mesenchyme. 
Forkhead proteins Foxa2, required for endoderm development (133), and 
Foxc1 or Foxc2, required for head mesenhyme and aortic arch formation 
(134-138), bind and activate Tbx1 transcription in their respective 
subdomains through this regulatory element. As menzionated above, 
Tbx1 responds to signals initiated by the secreted morphogen Sonic 
hedgehos (Shh); interestingly both Foxa2 and Foxc2 are downregualted 
in Shh null mutants, which die soon after birth with severe craniofacial 
defects (139, 140) and fail to maintain Tbx1 expression (102) suggesting 
a function for Forkhead proteins as an intermediary between Shh 
signalling and Tbx1 regulation.  
Maeda and colleagues showed that Tbx1 expression in the SHF is  also 
regulated by Forkhead proteins, through a combination of two 
evolutionary conserved Fox binding sites in a dose-dependent manner 
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(141); in addition Hu and colleagues (142) showed that mice 
hypomorphic for Tbx1 failed to activate expression of the forkhead 
transcription factor Foxa2 in the pharyngeal mesoderm, which contains 
cardiac outflow tract precursors, but not endoderm. They also identified a 
Fox-binding site upstream of Tbx1 that interacted with Foxa2 and was 
necessary for pharyngeal mesoderm and cardiac OFT expression of Tbx1, 
revealing an autoregulatory loop that may explain the increased cardiac 
sensitivity to Tbx1 dosage. 
Downstream of Tbx1, they found a fibroblast growth factor 8 (Fgf8) 
enhancer that was dependent on Tbx1 in vivo for regulating expression in 
the cardiac outflow tract, but not in pharyngeal arches (142). Consistent 
with its role in regulating cardiac outflow tract cells, Tbx1 gain of 
function resulted in expansion of the cardiac outflow tract segment 
derived from the anterior heart field as marked by Fgf10. These findings 
reveal a Tbx1-dependent transcriptional and signaling network in the 
cardiac outflow tract that renders mouse cardiovascular development 
more susceptible than craniofacial development to a reduction in Tbx1 
dose, similar to humans with del22q11. 
Thus, the genetic pathway emerging from available data is (Foxc1, 
Foxc2, Foxa2) → Tbx1 → (Fgf10, Fgf8). The links in this pathway are 
 45
still uncertain because they are based on transgenic experiments with 
artificial constructs, gene expression studies and luciferase assays in 
cultured cells. Definitive evidence will come from modification of the 
endogenous genetic elements that establish the links in vivo. In addition, 
it is very likely that the list of regulators and targets of Tbx1 will be 
extended considerably in the future. 
So, even if a great amount of data has been accumulate to date, many 
outstanding questions remain about the Tbx1 genetic pathway. 
To reconstruct a more detailed picture of the Tbx1 roles during embryonic 
development, the available knowledge concerning tissue and time–
specific effects of Tbx1 loss of function needs to be integrated with 
information about its targets, regulators and genetic interactors. 
To this aim, we previously generated a series of genotypes associated 
with a nearly continuous variation of Tbx1 mRNA dosage between 0 and 
100% of the wild-type level, by combining two different hypomorphic 
alleles: Tbx1Neo2 (143) and Tbx1Neo (120) and a null allele: Tbx1- (93). We 
have shown that the two hypomorphic alleles have uniformly low levels 
of expression across embryonic tissues. Tbx1Neo is a ‘weak’ hypomorphic 
allele with an expression level around 2–3% of the wild-type allele. 
Consistently with this finding, phenotypic analysis demonstrated that 
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Tbx1Neo/Neo embryos were nearly identical to Tbx1 null embryos (120). 
However, remarkably, such a low level of Tbx1 expression was sufficient 
to support palatogenesis, which is affected in null embryos, and to 
improve the alignment of the cardiac outflow tract (OFT) in some 
embryos (120). In contrast, the Tbx1Neo2 allele expressed 15–20% of the 
wildtype mRNA level. Both hypomorphic alleles were generated by 
inserting a PGKneo cassette into intron (120, 143), but in opposite 
orientation (Fig. 1A).  
Phenotypic analysis of the nine different genotypes revealed, as expected, 
that penetrance and expressivity increase as the Tbx1 level decreases, but 
the response is strikingly non-linear; the dynamic phenotypic response to 
dosage, in fact, is complex with different trends for different phenotypes, 
indicating that different developmental processes have different 
sensitivities to Tbx1 mRNA level.  
As part of the effort to identify new transcriptional targets of Tbx1, we 
performed a microarray-based transcriptome analysis through the above 
allelic series, in order to evaluate Tbx1 dosage-dependent gene expression 
changes in vivo. This analysis allowed us to identify several genes 
affected by Tbx1 expression levels; interestingly we found that the gene 
encoding the cardiogenic transcription factor Mef2c, is negatively 
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regulated by Tbx1, confirming recent reports. It has been uncovered, in 
fact, that different cell type populating the heart (e.g. cardiomyocytes, 
endothelial cells, smooth muscle cells) may derive from a single Isl1+ 
progenitor (144-146). Interestingly, Tbx1 is expressed in these 
multipotent cardiac progenitors: it enhances their proliferation and 
inhibits their differentiation, thus ensuring the maintenance of the 
progenitor population (147). Because Tbx1 can regulate Fgf8 expression 
in the mesodermal region that includes the SHF, some of its mitogenic 
activity could be mediated by the FGF signalling; on the other hand a 
negative effect on differentiation could be explained by Tbx1 negative 
regulation of the myogenic transcription factor Srf (Serum response 
factor), which, in turn, regulates the muscle transcription program (147). 
So our results suggest that Mef2c transcriptional repression could be 
another possible mechanism by which Tbx1 regulates the balance 
between proliferation and differentiation in the SHF. 
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CHAPTER 2 
Material and methods 
2.1 Mouse lines, breeding and genotyping 
All the mouse mutant alleles used in this study have been reported 
previously: Tbx1- (93), Tbx1Neo (120), Tbx1Neo2 (143), COET (148) and 
Mesp1Cre (149). Various homozygous and compound heterozygous 
mutants were generated by heterozygous mutant mating. Embryos were 
collected at E8.5 and E9.5, considering the day of observation of a 
vaginal plug to be E0.5. Mice were genotyped by PCR as described in the 
original reports. 
2.2 Cloning, plasmids and mutagenesis 
We have previously described the pCDNA-Tbx1-c-myc expression 
vector (120). 3X-MEF2-luc reporter construct (150) was kindly provided 
by Dr. Olson EN; pCDNA3.1-Gata4-c-myc-His and pCDNA3.1-Ils1 
were kindly provided by Dr. Schwartz RJ. 
The minimal SHF-specific enhancer of the mouse Mef2c gene described 
by Dodou et al. (2) was amplified by PCR and cloned into the pGL3-
Promoter Vector (Promega) so generating the Mef2c-Enh-Luc reporter 
construct. MutMef2c-Enh-Luc reporter construct was generated by 
substitution of three nucleotides in the conserved TBE of the original 
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Mef2c-Enh-Luc reporter construct, using the QuikChange II Site-
Directed Mutagenisis Kit (Stratagene).  
2.3 Cell culture and transfections  
EBRTcTbx1 cells were cultured in the absence of feeder cells in Glasgow 
minimal essential medium (GMEM, Sigma-Aldrich) supplemented with 
10% fetal calf serum (Hyclone), 1 mM sodium pyruvate (Invitrogen), 10-4 
M 2-mercaptoethanol (Sigma-Aldrich), 1x nonessential amino acids 
(Invitrogen), 1000 U/ml of leukemia inhibitor factor (LIF, Millipore) and 
200ng/ml of doxycycline (Sigma-Aldrich) on gelatine-coated dishes, at 
37 °C with 5% CO2. The incomplete removal of doxycycline has been 
reported to result in insufficient induction of Tet-off system (151). 
Therefore, the cells to be induced were washed twice with PBS, cultured 
for more than 3 hours in GMEM without doxycycline, trypsinized and 
replated onto new dishes. After 24 hours, cells were collected for RNA 
extraction.  
Mouse C2C12 myoblasts (ATCC) were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM, Invitrogen) supplemented with 10% fetal 
bovine serum (Hyclone) at 37% °C with 5% CO2. To allow cells to 
differentiate, medium was changed to DMEM medium supplemented 
with 2% horse serum (Hyclone). 
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C2C12 cells were transiently transfected using the PolyFect Transfection 
Reagent (QIAGEN); for each kind of experiment, the number of cells to 
be plated and the amount of DNA to be transfected were chosen 
accordingly to the manufacturer’s instructions. Cells were collected 24 
hours after transfection for RNA or protein extraction.   
2.4 Mycroarray analysis 
Total RNA was isolated from E9.5 embryos with nine different genotypes 
(Tbx1+/+, Tbx1Neo2/+, Tbx1Neo/+, Tbx1+/-, Tbx1Neo2/Neo2, Tbx1Neo2/Neo, 
Tbx1Neo2/-, Tbx1Neo/Neo and Tbx1-/- ) using TRIzol (Invitrogen) according to 
the manufacturer’s instructions. RNAs from three embryos of the same 
genotype were combined and cleaned using the RNeasy cleanup Kit 
(QIAGEN); RNA was then checked for quality using an Agilent 
bioanalyser and degraded samples were eliminated. Quantification was 
performed using spectophotometry. Procedures for cRNA preparation 
and GeneChip processing were performed following standard procedures 
(http://www.affymetrix.com). Biotinylated target cRNAs were hybridized 
to GeneChip Mouse Genome 430 2.0 arrays following standard 
procedure (Affimetrix). Three chip sets were run for RNA isolated from 
wild-type embryos and three for RNA isolated from embryos of each 
mutant genotype. Statistical comparisons of chip data were performed 
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using GC-Robust Multichip Analysis (ArrayAssist V2.6.1642.30743, 
Iobion informatics) with variance correction using two-tailed unpaired t 
tests against wild-type chips; a probe-set expression was considered 
altered if it had a P value < 0.05 vs. wild type. Genes with statistically 
significative differential expression across the allelic series, were further 
analyzed for their correlation to Tbx1 dosage, using Pearson's correlation 
coefficient test. A gene was considered highly correlated (or anti 
correlayed) to Tbx1 dosage, if it had a correlation coefficient with a P 
value < 0.05 within a 95% confidence interval. 
2.5 T-box binding element (TBE) analysis 
Mouse and human genomic sequences for all the 256 differentially 
expressed genes were obtained from both the Ensembl and UCSC 
Genome Browser web sites, and were aligned using rVISTA, a set of 
programs for comparing DNA sequences from two or more species.  No 
direct Tbx1 binding site has been identified so far; however Tbx1 can 
activate, in vitro, the Fgf10 promoter, through a conserved Tbx5 binding 
site (120). With the Transfac data base we defined the Tbx5 consensus 
DNA sequence (A/G/TG/AGTGNNA) using a position weight matrix 
(PWM) based on all published T-box binding element and we looked for 
evolutionary conserved Tbx5 binding elements, in the aligned sequences, 
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using the MATCH software. 
2.6 Quantitative Real-Time PCR (qRT-PCR) 
Total RNA was extracted from whole E9.5 wt and mutant embryos using 
TRIzol (Invitrogen), from C2C12 and EBRTcTbx1 cells using the 
RNeasy Mini Kit (QIAGEN). 1 ug of total RNA was reverse transcribed 
using SuperScript III (Invitrogen) according to the manufacturer’s 
instructions, in a total volume of 20 ul; the resulting cDNA was diluted 
1:10. qRT-PCR was performed using SYBR Green for the detection of  
fluorescence during amplification. Each amplification reaction contained 
25 ul of Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen), 0.2 
ug each of forward and reverse primers, and 1 or 2 ul of diluted cDNA. 
All primers were designed with annealing temperatures of 58-62 °C. PCR 
conditions were: 50°C for 2 minutes, 95°C for 10 minutes, 40 cycles of 
95°C for 15 seconds, 60°C for 1 minute, followed by a dissociation stage 
of 95°C for 15 seconds and 60°C for 15 seconds. All the genes were 
amplified on a 7900 HT Fast Real-Time PCR System (Applied 
Biosystems). At least three separate analysis were carried out for each 
gene. Melt curve analysis was performed after each run to check for the 
presence of non-specific PCR products and primer dimers. Ct values were 
related to copy numbers using standard curves, as described previously 
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(152); normalization was performed using GAPDH as an internal control 
as described (152). 
2.7 In situ hybridization 
Digoxygenin-labeled RNA probes were prepared by standard methods 
(Roche). Mef2c and Gata4 probes were kindly provided by Dr. Black BL. 
Embryos were dissected in di-ethylpolycarbonated (DEPC, Sigma 
Aldrich) treated PBS and fixed over night in 4% paraformaldeyde-PBS 
(Sigma Aldrich) at 4°C. 
For in situ hybridization on cryosections, embryos were cryoprotected 
with increasing concentrations of sucrose (Sigma Aldrich), treated with a 
mixture of 1 part 30% sucrose to 1 part O.C.T. for at least 2 hours at 4°C, 
embed in O.C.T. and cutted to generate 10-12 um sections. After 
postfixation in 4% paraformaldehyde-PBS, sections were incubated in 
Triethanolamine Buffer (0,2% acetic acid and 1% triethanolamine, Sigma 
Aldrich) containing acetic anhydride and washed twice in PBS for 5 
minutes. The sections were then prehybridized for 1 h at 70°C in the 
hybridization mix (50% formamide from Sigma Aldrich, 5x SSC, salmon 
sperm DNA 40 ug/ml and 25mg/ml yeast tRNA from Invitrogen). The 
probes were denatured for 5 min at 80°C and added to the hybridization 
mix (400 ng/ml). The hybridization reaction was carried out over night at 
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70; prehybridization and hybridization were performed in a box saturated 
with a 5x SSC – 50% formamide solution to avoid evaporation. After 
incubation, the sections were washed twice with MABT (50mM maleic 
acid, pH7.5, 250 mM NaCl and 0,1% Tween-20, Sigma Aldrich), treated 
with MABT containing 10% sheep serum for 1 hour at room temperature 
and then incubated with alkaline phosphatase-coupled anti-digoxigenin 
antibody (Roche) diluted 1:2000 in MABT containing 10% sheep serum, 
over night at 4°C. The day after, sections were washed with MABT and 
equilibrated for 5 min in Buffer 3 (Tris-HCl 100mM, NaCl 100mM, and 
MgCl2 50mM, pH 9.5); color development was performed at room 
temperature (time depending on the amount of transcripts to be detected) 
in Buffer 3 containing NBT and BCIP (Roche). Staining was stopped by 
a wash in  PBS containing 0,1% Tween-20; sections were rehydrated for 
5 minutes in deionized water and then dehydrated through successive 
baths of EtOH (70, 95, and 100%) and xylol, and mounted in Eukitt resin 
(O. Kindler GmbH & Co.). 
Whole mount in situ hybridization was performed according to the 
previously published methods (In situ Hybridization. A Practical 
Approach. Edited by D.G. Wilkinson. IRL Press, Oxford. 1992). 
At least three somite staged wt and mutant embryos were analyzed with   
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each probe. 
2.8 Western Blotting 
Total proteins were extracted after cell lysis with the RIPA buffer (1% 
NP40, 0.5% NaDoc, 0.1% SDS in PBS, protease inhibitor (Roche). 
Nuclear and cytoplasmic proteic extracts were prepared using the NE-
PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific). 
The primary antibodies were rabbit-anti-Tbx1 (Zymed, 1:500), goat-anti-
Mef2c (Santa Cruz Biotechnology, 1:500), rabbit-anti-Gata4 (Santa Cruz 
Biotechnology, 1:1000), monoclonal anti-alpha-Tubulin (Sigma-Aldrich, 
1:5000) and rabbit-anti-beta-Actin (BioVision 1:5000). The secondary 
antibodies were: HRP-conjugated anti-rabbit and anti-mouse antibodies 
(GE Healthcare, 1:10.000), HRP-conjugated anti-goat (Santa Cruz 
Biotechnology, 1:5000). The HRP-derived signal was detected using the 
Amersham ECL and ECL Plus Western Blotting Detection Reagents (GE 
Healthcare).  
2.9 Luciferase assays 
For luciferase assays, mouse C2C12 myoblasts were plated in 24-wells 
and transfected with PolyFect Transfection Reagent (QIAGEN) 
according to the manufacturer’s instructions. 3X-MEF2-luc, Mef2c-Enh-
Luc and MutMef2c-Enh-Luc reporter constructs (and for single 
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experiments the pCDNA-Tbx1-c-myc, pCDNA3.1-Gata4-c-myc-His and 
pCDNA3.1-Ils1 plasmids) were always co-transfected with a pCMV-b-
Gal expression vector (Clontech); at 24 hours after transfection, cell 
extracts were prepared and activities of b-galactosidase and firefly 
luciferase were measured using the Luciferase Assay System (Promega) 
and the Beta-Glo Assay System (Promega) respectively, on a GLOMAX 
96 microplate luminometer (Promega). Relative luciferase activity 
(firefly luciferase for reporter and b-galactosidase for normalization of 
transfection efficiency) was measured following manufacturer’s 
instructions (Promega); to correct for transfection efficiency, the 
luciferase activity was divided by the b-galactosidase activity in every 
case. The data represent the means and standard deviations of at least, 
three independent transfections.  
2.10 RNA interference 
Gata4 Interference in C2C12 myoblasts was achieved by using a set of  
four different siRNAs specifically directed against the mouse Gata4 locus 
(ON-TARGET plus SMART Pool, Thermo Scientific). As negative 
control we used a pool of siRNAs that virtually targeted no mouse genes 
(ON-TARGET plus Negative Control, Thermo Scientific). Cells were 
plated in 6-wells and transfected with 50nM/well of siRNAs using 
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Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
instructions. Gata4 mRNA level was measured by qRT-PCR and Gata4 
protien level by Western Blotting as decribed above.  
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CHAPTER 3 
Results 
3.1 Mycroarray analysis of Tbx1 dosage-dependent gene expression 
changes in vivo 
We have previously generated a series of genotypes associated with a 
nearly continuous variation of Tbx1 mRNA dosage between 0 and 100% 
of the wild-type level (Figure 1) by combining two different 
hypomorphic alleles, Tbx1Neo2 (143) and Tbx1Neo  (120) and a null allele, 
Tbx1-  (93).  
To evaluate Tbx1 dosage-dependent gene expression changes in vivo, we 
performed a microarray-based transcriptome analysis, across the allelic 
series, at E9.5. 
This analysis is aimed at identifying genes with quantitatively changed 
expression when compared to wild type: differential expression of 
molecular markers may indicate a direct target of Tbx1, or an indirect 
target whose altered expression gives clues as to developmental defects in 
particular tissues or cell populations. 
Statistical analysis identified 256 genes differentially expressed across 
the allelic series and, even if Tbx1 is known to act as a transcriptional 
activator, we found 120 genes whose expression profile is correlated to 
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Tbx1 dosage and 136 genes whose expression profile is anti-correlated to 
it. Among the 256 differentially expressed genes, 52 changed in a manner 
that was highly correlated (or anti-correlated) to Tbx1 expression. 35 out 
of 52 highly correlated genes were upregulated and 17 were 
downregulated in Tbx1 mutant embryos (Figure 2A). 
Classification of the 256 microarray genes into gene ontology (GO) 
categories revealed downregulation of apoptosis-related genes; this result 
is consistent with the role of Tbx1 in promoting cell proliferation in 
several tissues. Whereas highly sensitive Tbx1-regulated genes account 
for only 52 out of 256 genes altered in Tbx1 mutants, the relative ratios 
between functional classes of genes affected were maintained, suggesting 
that no single functional class of gene is more sensitive to changes in 
Tbx1 dosage (Figure 2B). 
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Figure 1. Tbx1 mRNA dosage in E9.5 embryos with different 
genotypes. (A) Schematic drawings of the Tbx1 alleles used in this 
study. (B) Relative expression level of Tbx1 associated with the 
genotypes studied. At least three embryos per genotype were assayed. 
Error bars indicate standard error.  
(A) 
(B) 
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Figure 2. Schematic representation of microarray analysis results. (A) 
Percentage of correlated and anti-correlated genes. (B) GO classification of 
differentially expressed genes. 
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3.2 Conserved T-box binding element analysis 
No direct Tbx1 binding sites have been identified so far, anyway Agarwal 
and colleagues (153) have shown in vivo that Fgf10 requires Tbx5 for 
initiation of its expression, whereas Wnt signaling via LEF1 and TCF1 is 
required to sustain high levels of Fgf10 expression. This is supported by 
their in vitro transactivation data, which show powerful activation of the 
Fgf10 promoter by TBX5, through an evolutionary conserved T-box 
binding element (TBE) located in the 5’ region of the Fgf10 gene. We 
previously showed that Tbx1 can directly activate the Fgf10 promoter 
through that TBE in a tissue culture assay (120), raising the intriguing 
possibility that different T-box transcription factors may share target 
genes. 
So we used the Tbx5 consensus DNA sequence, loosely defined as 
A/G/TG/AGTGNNA using a position weight matrix (PWM) based on all 
published T-box binding sites, to look for evolutionary conserved T-box 
binding elements. The TRANSFAC data base and the rVISTA program 
were used to align 10kb of upstream human and mouse genomic regions 
from all 256 differentially expressed genes; we also analyzed the intronic 
regions of highly correlated genes.  
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Totally we found one or more potential TBEs in the 10kb upstream 
region of 90/256 differentially expressed genes, 55 of which were anti-
correlated and 35 correlated to Tbx1 dosage.  
25/90 genes with a potential TBE in their upstream region belong to the 
highly correlated group, which includes 53 genes: so the 47% of the 
highly correlated genes carries a potential Tbx1 binding site in its 3’ 
upstream region. We also found in some of these genes and in 12 more 
highly correlated genes, one or more putative TBEs in the intronic 
regions: so totally, counting both the upstream and the intronic regions, 
we found that the 70% of the highly correlated genes shows a potential 
TBE, evolutionary conserved between mouse and human. This 70% 
includes 25 genes anti-correlated and 11 genes correlated to Tbx1 dosage.  
3.3 Selection of Tbx1 candidate transcriptional targets  
We selected a number of genes for further validation, following 
essentially three main criterions: 
? High correlation with Tbx1 dosage (Pex2, Vps33a, Morf4l1, Srmm1,  
Hibch, Plagl1, C1d, Commd3) 
? Developmental relevance and known expression pattern (Mef2c, 
Foxp1) 
? Involvement in signalling pathways (Fos, Tgfbr3) 
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3.4 Validation of selected Tbx1 candidate transcriptional targets 
By quantitative Real-time PCR (qRT-PCR) of mRNA from Tbx1 mutant 
embryos and also from an in vitro gain of function model, we confirmed 
the microarray results on a subset of selected genes, namely Pex2, 
Vps33a, Morf4l1, Tgfbr3, and Mef2c. 
3.4.1 Pex2: peroxin2 
Peroxins are proteins involved in peroxisome biogenesis and are encoded 
by PEX genes. The human PEX2 (154) gene encodes a 35-kDa 
peroxisomal integral membrane protein, peroxin 2 (Pex2p) which is a 
member of the  PEX zinc finger protein family (155-158). Mutations in 
the PEX2 gene are the primary defect in a subset of patients with 
Zellweger syndrome and related peroxisome biogenesis disorders 
(neonatal adrenoleucodystrophy, and infantile Refsum disease which is 
the most mild) that result in abnormal neuronal migration in the central 
nervous system and severe neurologic dysfunction due to the lack of 
functional peroxisomes (159). Homozygous Pex2-deficient mice survive 
in utero but die several hours after birth. The mutant animals do not feed 
and are hypoactive and markedly hypotonic. The Pex2-deficient mice 
lack normal peroxisomes but do assemble empty peroxisome membrane 
ghosts. They display abnormal peroxisomal biochemical parameters, 
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including accumulations of very long chain fatty acids in plasma and 
deficient erythrocyte plasmalogens. Abnormal lipid storage is evident in 
the adrenal cortex, with characteristic lamellar–lipid inclusions. In the 
central nervous system of newborn mutant mice, there is disordered 
lamination in the cerebral cortex and an increased cell density in the 
underlying white matter, indicating an abnormality of neuronal migration 
(160). 
3.4.2 Vps33a: vacuolar protein sorting 33A  
Hermansky–Pudlak syndrome (HPS) is a disorder of organelle biogenesis 
in which oculocutaneous albinism, bleeding, and in most cases 
pulmonary fibrosis result from defects of melanosomes, platelet-dense 
granules, and lysosomes (161-164). Somewhat similar disorders, 
Chediak–Higashi and Griscelli syndromes, are additionally associated 
with severe immunodeficiency (162, 163). Important clues to the 
pathogenesis of these disorders have come from the mouse, in which 
more than 16 loci have been associated with mutant phenotypes similar to 
those of human HPS, Chediak–Higashi syndrome, and Griscelli 
syndrome (165, 166). Several of these genes have been identified and in a 
number of cases have been shown to result in homologous disorders in 
mice and humans (162-164). Although the functions of many of the 
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corresponding gene products remain unknown, several are involved in 
various aspects of trafficking proteins to nascent organelles, particularly 
melanosomes, lysosomes, and cytoplasmic granules. In the yeast, have 
been implicated in biogenesis of the cytoplasmic vacuole, which 
resembles in its function the lysosome of higher organisms, more than 65 
proteins including the products of more than 40 vacuolar protein-sorting 
(vps) loci required for trafficking newly synthesized proteins from the 
Golgi to the vacuole (167, 168). It seems likely that at least as many 
proteins are associated with organellar biogenesis in mammals. 
A subset of these genes, the four class C vps genes, which mutations 
exhibit the most severe disruption of vacuolar morphology, is necessary 
for the delivery of endocytic and biosynthetic cargo in yeast, and also in 
Drosophila. Corrispondently, in humans have been cloned and 
characterized four genes corresponding to class C VPS mutants (VPS18, 
VPS11, VPS16, and VPS33 with two isoforms a and b), that on the basis 
of phenotype could be HPS genes (169, 170). Suzuki and colleagues 
(171) have mapped and positionally cloned the mouse buff (bf) locus, 
which is characterized by recessive coat-color hypopigmentation and 
mild platelet-storage pool deficiency; they find that mouse bf results from 
a missense substitution in Vps33a, a homologue of yeast vps33 and 
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human VPS33a. The bf mutation results in defective melanosome 
morphology and melanogenesis both in vivo and in vitro. Expression of 
wild-type Vps33a in transfected mouse bf-mutant melanocytes 
complements this aberrant phenotype, whereas expression of bf-mutant 
Vps33a does not. These results establish murine bf as a murine 
homologue to the yeast vps33 mutant and suggest VPS33A as a candidate 
gene for some cases of human HPS. 
3.4.3 Morf4l1: mortality factor 4 like 1  
The human MRG/MORF family of transcription factor-like genes which 
includes MORF4, MORF-related gene on chromosome 15 (MRG15 also 
known as MORF4L1), and MORF-related gene on the X-chromosome 
(MRGX), since its initial discovery, has been linked to cell proliferation, 
transcriptional regulation, and DNA damage repair. 
In the earliest studies, MRG15 was shown to associate with at least two 
complexes of nuclear proteins, MRG15-associated factors 1 and 2 
(MAF1 and MAF2). MAF1 is composed of MRG15, retinoblastoma 
(Rb), and PAM14 (172); Rb can, in fact, associate with both MRG15 and 
MRGX. The association with MRG15 activates the Bmyb promoter in 
both EJ and HeLa cells (173), while the association with MRGX activates 
the B-myb promoter in HeLa while repressing it in EJ cells (174). This 
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implies a potential mechanism of the MRG family’s effect on cellular 
proliferation. MAF2 contained MRG15 bound to hMOF, a MYST family 
HAT.19 Further, it was demonstrated that MRG family proteins are 
components of mSin3A/Pf1/HDAC complexes. The chromodomain of 
MRG15 is bound by the plant homeodomain zinc finger protein Pf1, 
which acts as an adaptor between the two transcriptional repressors 
mSin3A and the transducin-like enhancer of split (TLE). Additionally, 
MRG15 alone or MORF4 or MRGX fused with the Gal4 DNA binding 
domain can bind the mSin3A–TLE corepressor complex and induce 
transcriptional repression (175). Finally, MRG15 was identified in the 
TIP60 HAT complex implicated in transcriptional activation in addition 
to DNA repair and apoptosis (176, 177). Further underscoring the 
importance of these two genes, knockdown or deletion of either gene in 
mice results in a similar phenotype including DNA repair defects and 
embryonic lethality (178); in particular with the majority of the embryos 
succumbing between E14.5 and birth (179). The null embryos are 
approximately 74% the size of their wild-type littermates with most of 
their tissues proportionately smaller. In addition to their small size, the 
embryos appear pale, suggesting possible circulation, vascularization, 
and/or hematopoiesis defects. Of those that survived to birth, all died 
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soon thereafter and examination revealed severe abnormalities in multiple 
organ systems. The null lungs contained reduced alveolar space and 
likely failed to inflate following birth. The hearts of the neonates were 
grossly defective, with ventricular and atrial hypertrophy, enlarged 
cardiomyocytes, and myocardial fiber disarray. Additionally, the 
neonates exhibited congestion in multiple organs, but of the liver, lung, 
and spleen in particular. The skin of the neonates was thinner and less 
keratinized than the wild-type control with diminished cell number and 
BrdUpositive staining in the basal cell layer (179). 
Pena et al. (180) studied the growth properties of mouse embryonic 
fibroblasts (MEFs) from E13.5 embryos, founding correspondence with 
what predicted from the gross histology of the embryos. In particular, the 
Mrg15−/– MEFs show a significantly reduced growth curve than MEFs 
cultured from wild-type littermates. A colony size distribution assay also 
revealed a smaller percentage of null MEFs in colonies of greater than 
four cells with a concomitant increase in null MEFs in single-cell 
colonies, implying an inability to divide. Finally, null MEFs tended to 
adopt the large, flattened morphology characteristic of senescent cells at 
an earlier passage than the wild-type controls. 
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Some rescue was achieved, however, when MRG15 was reintroduced by 
adenoviral infection, indicating that the observed growth defects were 
directly linked to Mrg15 deficiency (178). To better understand the 
mechanism of diminished cell cycle progression, Pena and colleagues 
(180) also examined the tumor suppressor p21, p53, and p19ARF 
expression. While the upstream regulators of p21, p53, and p19ARF 
showed no change in expression, p21 expression was significantly 
increased in the MRG15 null MEFs as compared to the wild-type. 
3.4.4 Tgfbr3: transforming growth factor, beta receptor III 
The transforming growth factor b (TGFb) superfamily is composed of  
homodimeric polypeptide growth factors, including TGFb isoforms, bone 
morphogenetic proteins, growth and differentiation factors, activins and 
inhibins (181). The TGFb signaling pathway has essential roles in 
regulating many cellular responses including proliferation, 
differentiation, migration and apoptosis (182-186). There are three TGFb 
isoforms, TGFb1, TGFb2 and TGFb3, which are encoded by distinct 
genes and expressed in both a tissue-specific and a developmentally 
regulated manner. TGFb exerts its biological function through binding to 
three high-affinity cell-surface receptors, the TGFb type I, type II and 
type III receptors (TbRI or ALK-5, TbRII and TbRIII or betaglycan, 
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respectively). TbRI and TbRII contain serine/threonine protein kinases in 
their cytoplasmic domains. Upon ligand binding, TbRII recruits and 
phosphorylates TbRI, activating its kinase activity to initiate intracellular 
signaling. TbRI signals by directly phosphorylating Smad2 and Smad3, 
which form a complex with the common mediator Smad4, translocate to 
nucleus and regulate gene transcription (187, 188). While Smad-
dependent pathways represent a major mechanism for TGFb signaling, 
crosstalk and signaling through Smad-independent pathways, including 
the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-
kinase (PI3K)/Akt pathways has been reported (189-195).  
TbRIII is the most abundant TGFb receptor and is traditionally thought to 
function as a co-receptor, binding TGFb and presenting it to TbRII (196). 
This is particularly important for the TGFb2 isoform, which cannot bind 
TbRII independently. In addition, several studies support essential, non-
redundant roles for TbRIII in mediating TGFb sensitivity in intestinal 
goblet cells (197), in the mesenchymal transformation of chick 
embryonic heart development (198) and for mouse embryonic 
development (199). It has been reported the frequent loss of TbRIII 
expression in human breast, prostate and ovarian cancers, with loss of 
expression correlating with disease progression and re-expression studies 
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establishing a direct role for TbRIII in regulating cancer cell migration 
and invasion in vitro, and angiogenesis and metastasis in vivo. 
TbRIII has a short cytoplasmic domain without kinase activity; while this 
cytoplasmic domain is not essential for mediating the presentation role, it 
does contribute to TbRIII/TGFb-mediated inhibition of proliferation 
(200, 201). In L6 myoblasts, TbRIII expression enhanced TGFb1-
mediated growth inhibition, with this effect mediated, in part, by the 
TbRIII cytoplasmic domain. The effects of TbRIII were not due to altered 
ligand presentation or to differences in Smad2 phosphorylation. Instead, 
TbRIII specifically increased Smad3 phosphorylation, both basal and 
TGFb-stimulated Smad3 nuclear localization and Smad3-dependent 
activation of reporter genes independent of its cytoplasmic domain. 
Conversely, SB431542, a TbRI inhibitor, as well as dominant-negative 
Smad3 specifically and significantly abrogated the effects of TbRIII on 
TGFb1-mediated inhibition of proliferation. TbRIII also specifically 
increased p38 phosphorylation, and SB203580, a p38 kinase inhibitor, 
specifically and significantly abrogated the effects of TbRIII/TGFb1-
mediated inhibition of proliferation in L6 myoblasts and in primary 
human epithelial cells. Importantly, treatment with the TbRI and p38 
inhibitors together had additive effects on abrogating TbRIII/TGFb1-
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mediated inhibition of proliferation. In a reciprocal manner, short hairpin 
RNA-mediated knockdown of endogenous TbRIII in various human 
epithelial cells, attenuated TGFb1-mediated inhibition of proliferation. 
Taken together, these data demonstrate that TbRIII contributes to and 
enhances TGFb-mediated growth inhibition through both TbRI/Smad3-
dependent and p38 mitogen activated protein kinase pathways (200, 201). 
3.4.5 Mef2c: myocyte enhancer factor 2C 
Mef2c belongs to the MEF2 (myocyte-specific enhancer-binding factor 
2) subfamily of MADS (named for MCMI, wich regulates mating type-
specific genes in yeast, Agamous and Deficiens, which have a homeotic 
function in plants, and Serum Response Factor, which mediates serum-
inducible transcription) transcription factors (202). The MADS domain is 
a 56-amino acid motif that mediates DNA binding, homo- and 
heterodimerization, and interaction with basic helix-loop-helix proteins 
(202-209). The four MEF2 family members (MEF2A, MEF2B, MEF2C, 
MEF2D) are highly homologous within the MADS domain and an 
adjacent 26-amino acid region, known as the MEF2 domain, but they are 
divergent in their carboxyl termini. Additional complexity of this family 
of regulators arises from alternative splicing of MEF2 transcripts, 
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yielding isoforms with common DNA-binding domains and unique 
carboxyl terminal regions. 
MEF2 genes are expressed in cardiac, skeletal, and vascular smooth 
muscle cells, endothelial cells, several types of hematopoietic cells and 
discrete neurons of the central nervous system (210-214). Accordingly, 
several lines of evidence have implicated members of this family in 
transcriptional regulation of muscle-specific genes and of genes regulated 
by extracellular signals (215). 
Members of MEF2 transcription factor family play key roles in cardiac 
myogenesis. Mef2c in particular is among the earliest markers of the 
cardiac lineage with its expression detectable in mesodermal cells that 
give rise to the primitive heart tube, at about E7.5, shortly after the 
expression of the Nkx2.5 and Gata genes (210, 214, 216-222). By E8.5, 
Mef2c (together with Mef2a and Mef2d) transcripts are detected in the 
myocardium and interestingly at the time of cardiac looping, they are 
present in the left ventricle and atria but are much more robustly 
expressed in the right ventricle, outflow tract and pharyngeal mesoderm. 
By E9.0, Mef2c is expressed in rostral myotomes, where its expression 
lags by about a day behind that of Myf5 and several hours behind that of 
myogenin (210). Its expression is observed in muscle-forming regions 
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within the limbs at E11.5 and within muscle fibers throughout the embryo 
at later stages. Mef2c is also expressed in endothelial cells, surrounding 
mesenchyme and smooth muscle cells (SMCs) of the developing 
vasculature of the embryo (210, 223). In the absence of Mef2c, the 
endothelial cell plexus is not stabilized and SMCs do not differentiate 
suggesting that it plays multiple roles in vascular development, being 
required for endothelial cell interactions and in mesenchymal cells 
surrounding the endothelial network, for their responsiveness to 
endothelial cell signaling, their migration or their differentiation. The 
apparent failure of endothelial cells to interact properly to form a vascular 
plexus in Mef2c mutant embryos, could also reflect an underlying defect 
in cell adhesion. 
After E12.5, Mef2c transcripts are detected at high levels in specific 
regions of the brain too (206, 224, 225).  
In agreement with the microarray results, Pex2 and Morf4l showed down-
regulated expression in Tbx1-/- embryos at E9.5, while Vps33a and Mef2c 
were up-regulated (Figure 3). 
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Figure 3. qRT-PCR on mRNA from E9.5 wt and Tbx1 null mutant embryos. 
Pex2 and Morf4l1 are down-regulated in Tbx1 null mutants, while Vps33a 
and Mef2c are up-regulated. 
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To confirm the microarray results, we also used an in vitro gain-of-
function model, a Tbx1-expressing tetracycline (Tc) inducible mouse 
embryonic stem cell line, previously established in our laboratory using 
the ROSA-TET system described by Masui et al. (226). Tc-regulated 
transgene expression systems, known as Tet-off and Tet-on systems, have 
been widely applied to a variety of biological materials, including 
mammalian cells (227, 228). The Tet-off system is based on a Tc-
regulatable transactivator (tTA), which induces transcription in the 
absence of Tc or its analog doxycycline (Dox) through binding to the 
hCMV-1 promoter. This promoter is composed of a Tc-responsive 
element (TRE) followed by a minimal promoter of the human 
cytomegalovirus (hCMV) immediate early gene. The tTA protein is a 
fusion protein composed of the TRE-binding domain of Tc repressor 
protein and the herpes simplex virus VP16 activation domain (229). 
Alternatively, the Tet-on system uses a reverse Tc-regulated 
transactivator (rtTA) which binds TRE and induces transcription of the 
transgene in the presence of Dox (230). The ROSA-TET system allows 
researchers to establish ES cell lines carrying a Tc-regulatable transgene 
at the ROSA26 locus that is regarded as a locus from which proteins can 
be expressed ubiquitously at a moderate level. This system is based on a 
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knock-in step of a construct carrying both loxP and its mutant sequences 
(loxPV) into the ROSA26 locus, followed by a subsequent exchange step 
that introduces a cDNA to be Tc-regulated to the locus, using the 
recombinase-mediated cassette exchange reaction (Figure 4).  
In our laboratory, an exchange vector carrying the Tbx1 cDNA was co-
transfected along with a Cre-expression vector into EBRTcH3 cells 
which had been derived from EB3 cells by the knock-in step, to establish 
an ES cell line (named EBRTcTbx1) expressing Tbx1 under the control 
of the ROSA26 promoter in a Tc-dependent manner (Figure 5A). In Tc- 
medium, tTA binds to the hCMV-1 promoter, inducing expression of 
Tbx1-IRES-Venus. 
 By qRT-PCR on mRNA from cells cultured for 24 hours in the absence 
of doxycycline, we observed a Tbx1 mRNA level increased of about 45 
folds, confirming the efficiency of the system (Figure 5B).  
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Modified from Masui et al., 2005 
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- Tc 
(B) 
Figure 5. Induction of expression in the ROSA-TET system (A) Schematic representation 
of the induction of Tbx1-IRES-Venus expression. (B) qRT-PCR on mRNA from 
EBRTcTbx1 cells grown in ES medium with and without Tc.  
Figure 4. Experimental strategy to generate the ROSA-TET locus and the desired 
locus locus. 
(A) 
Tbx1 
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In these conditons Mef2c, Tgfbr3 and Vps33a were down-regulated, while 
Morf4l1 and Pex2 showed an increased expression (Figure 6).  
Totally the in vivo loss-of-function and in vitro gain-of-function systems 
allowed us to confirm the microarray results on an half of selected genes; 
however we decided to focused our attention on understanding the 
mechanism by which Tbx1 regulates Mef2c expression, for several 
reasons. First, Mef2c seems to have a key role in the transcriptional 
pathways controlling myoblast differentiation in the second heart field; 
second, Tbx1 is strongly expressed in that tissue and it is required for 
mesodermal cell proliferation. Finally, our microarray results showed a 
negative regulation of Mef2c by Tbx1: taken together these data 
suggested a putative model in which Tbx1 can exerts its anti-
differentiative role on SHF mesodermal cells, through a mechanism 
involving Mef2c transcriptional repression. 
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Figure 6. qRT-PCR on mRNA from EBRTcTbx1 cells. Mef2c, Tgfbr3 and 
Vps33a are down-regulated in Tbx1 over-expressing cells, while Pex2 and 
Morf4l1 are up-regulated.  
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3.5 Mef2c is specifically overexpressed in the second heart field of 
Tbx1-/- mutant embryos 
 In situ hybridization (ISH) served as an independent method of 
validating the Mef2c microarray results, enabling assessment of 
qualitative gene expression changes in Tbx1 null mutant embryos. 
Interestingly, ISH on embryo criosections at E9.5 revealed upregulation 
of Mef2c in the second heart field of Tbx1-/- mutants compared to wt 
littermates (Figure 7).  
3.6 Mef2c expression is Tbx1 dosage-dependent in transfected C2C12 
myoblasts 
In order to confirm the microarray results for Mef2c, we also used an in 
vitro gain of function model, represented by C2C12 myoblasts. By qRT-
PCR on mRNA from C2C12 cells transfected with different amount of a 
Tbx1 expressing vector (pCDNATbx1-c-myc), we confirmed that Mef2c 
expression is Tbx1 dosage-dependent (Figure 8). 
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WT 
-/- 
-/- 
Figure 7. In situ hybridization on criosection of E9.5 wt and Tbx1 null mutant 
embryos with a digossigenin-labeled Mef2c antisense probe. Mef2c is 
specifically up-reguated in the SHF of Tbx1 null mutants. 
WT 
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Figure 8. qRT-PCR on mRNA from transfected C2C12 myoblasts. Mef2c expression 
is Tbx1-dosage dependent. 
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3.7 Mef2c protein level is affected by Tbx1 dosage in transfected 
C2C12 myoblasts 
To demonstrate that Mef2c negative regulation by Tbx1, also affects 
Mef2c protein level, we performed a Western Blotting analysis on total 
protein extracts from transfected C2C12 myoblasts. 
We found a low protein level reduction (Figure 9), but we were able to 
confirm that result in multiple experiments (data not shown). 
In addition, we performed luciferase assays on  transfected C2C12 cells, 
using a minimal MEF2-luciferase reporter construct (3X-MEF2-luc), in 
which firefly luciferase expression is driven by a thymidine kinase 
promoter with three upstream tandem copies of a high-affinity MEF2 
binding site from the desmin gene, termed desMEF2 (150, 231). 
Hui Li and Yassemi Capetanakil (232) showed that Mef2c (and also other 
members of MEF transcription factor family) was able to bind that site, 
so trigging the desmin gene muscle-specific transcription in concert with 
bHLH myogenic regulator family. Since it has been demonstrated that 
Mef2c is a direct transcriptional target of Isl1 and Gata4 factors in the 
SHF, during mouse embryonic development (2), we performed luciferase 
assays   on    C2C12   cells    transfected   with    the    reporter   construct  
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pCDNA3.1 
pCDNA-Tbx1-c-myc 1 ug 
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anti-Mef2c 
anti-Tbx1 
anti-α-Tubulin 
Figure 9. Western Blotting analysis on transfected 
C2C12 myoblasts. Tbx1 dosage affects Mef2c protein 
level. 
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together with different amounts of a Gata4 or Isl1 expressing vector in 
order to test the functionality of the system. As expected, our experiments 
showed an increased luciferase activity in the presence of Gata4 or Isl1 
(Figures 10A and 10B); we also performed luciferase assays on C2C12 
myoblasts transfected with different amounts of a Tbx1 expressing 
vector, but unfortunately, we were not able to appreciate a decreased 
luciferase activity as result of a lower Mef2c protein level due to Tbx1 
over-expression (Figure 10A). 
A possible explanation for a such as result was that probably in our 
experiment, the basal luciferase activity was too low to appreciate a 
decrease in the presence of Tbx1; so we decided to perform luciferase 
assays on C2C12 cells transfected with both Gata4 (or Isl1) and Tbx1 
expression vectors. 
Our results showed that Tbx1 was able to interfere with Gata4-dependent 
luciferase activity enhancement (Figure 10C), but not with the Isl1-
dependent one (Figure 10D), suggesting that Tbx1 could regulated Mef2c 
expression through a mechanism requiring Gata4 activity. 
It has been shown by Liao et al. that Gata4 is overexpressed in Tbx1-/- 
mutants; since Mef2c is  regulated   by  Gata4 (2),  one  can  argue  that  
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Figure 10. Luciferase assays on transfected C2C12 myoblasts. (A, B) Mef2c 
protein activity is sensitive to Gata4 and Isl1 dosage, but not to Tbx1 dosage. 
(C,D) Tbx1 interferes with Gata4- but not with Isl1-dependent activity of 
Mef2c protein. 
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reduced Mef2c protein level observed in our experiments is just the result 
of a Gata4 negative regulation by Tbx1;  this  hypothesis  seems  unlikely 
since we performed our luciferase assays on cells transfected with a 
Gata4 expression vector carrying the Gata4 cDNA without the regulatory 
regions that could be, in vivo, targeted by Tbx1. Theoretically, the Tbx1 
negative effect on endogenous Gata4 could contributes to the reduced 
Mef2c protein level observed in Gata4/Tbx1 transfected cells, but this 
effect seems to be negligible, since we did not observed any significant 
decreased Mef2c protein level in Tbx1 and Isl1/Tbx1 overexpressing 
cells. So it seems to be more likely the hypothesis of a Tbx1 mechanism 
of action affecting Gata4 protein activity rather than Gata4 gene 
transcription. 
3.8 Conserved T-box binding element analysis of Mef2c locus 
Our first analysis for conserved TBEs was not able to find any potential 
Tbx1 binding site in the 10kb upstream region of Mef2c locus; both our in 
vivo and in vitro results, however, suggest a possible negative regulation 
of Mef2c by Tbx1. So, as part of the effort to understand the mechanism 
by which Tbx1 regulates its expression, we decided to extend our 
analysis also to the intronic regions of Mef2c locus. Using the 
TRANSFAC data base and the rVISTA program, we found 91 potential 
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Tbx1 binding sites evolutionary conserved between human and mouse; 
this result is not surprising since all the regulatory regions of Mef2c gene, 
so far identified, reside in its intronic regions. 
In particular, by generating a Mef2c-lacZ transgenic mouse, Dodou and 
colleagues identified a minimal intronic enhancer that specifically directs 
Mef2c expression in the second heart field (2). They looked for cardiac-
specific transcription factor binding sites and found that this conserved 
regulatory region carries three conserved candidate binding sites for the 
Gata family of transcription factors and two conserved perfect consensus 
elements for the LIM-homeodomain transcription factor Isl1. In addition, 
they identified two candidate E boxes, representing potential binding sites 
for Hand factors, and a putative Nke binding site for Nk class factors 
such as Nkx2.5. However, among all the sites in the enhancer, robust 
binding by putative transcriptional regulators, was only detected for two 
of the Gata elements and for both the Isl sites. 
The cardiac Gata transcription factors, Gata4/5/6, are expressed more 
broadly than the second heart field restricted pattern of the Mef2c-lacZ 
transgene described in Dodou study (216, 219-221). The broader 
expression pattern of the Gata factors suggests that additional regulators 
must be required to restrict enhancer function to the second heart field. 
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Indeed, they also showed that the Mef2c enhancer is directly bound by 
Isl1. As is the case for the Gata factors, Isl1 expression within the embryo 
is broader than the pattern directed by the Mef2c enhancer they described, 
but expression of Isl1 within cardiogenic lineages appears to be limited to 
the anterior heart field (114). Thus, their data suggest a model in which 
Mef2c anterior heart field-specific expression is dependent on the 
combined activities of Isl1 and Gata4; interestingly, one of the putative 
Tbx1 binding sites we identified, also resides in the conserved SHF-
specific enhancer (Figure 11). This observation agrees with our previous 
results suggesting that Tbx1 can negatively regulate Mef2c expression by 
interfering somehow with Gata4 activity, may be by preventing binding 
to its sites in the enhancer. On the other hand, these data also open the 
question of whether the Mef2c regulatory mechanism involves a direct 
Tbx1 binding to the SHF-specific enhancer.  
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Figure 11. Alignment of conserved mouse and human sequence in the necessary and 
sufficient region of the Mef2c SHF enhancer. The enhancer carries a putative Tbx1 
binding site. 
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3.9 Mef2c regulation by Tbx1 seems to be mediated by Gata4  
To test if Tbx1 could regulate Mef2c expression through the SHF-specific 
enhancer described by Dodou et al., we cloned it upstream of a luciferase 
gene, which expression was driven by a minimal SV40 promoter, so 
generating the Mef2c-Enh-Luc reporter construct. 
Luciferase assays were performed on C2C12 transfected with different 
amount of a Tbx1 expression vector; as control we used Gata4- and Isl1-
overexpressing cells. As expected, we found an increased luciferase 
activity in Gata4 or Isl1 transfected C2C12 cells, compared to the control 
empty-vector transfected cells (Figure 12A). 
Unfortunately we were not able to appreciate any significant difference, 
in luciferase activity between Tbx1-overexpressing and control C2C12 
myoblasts, probably because, also in this case, basal luciferase activity 
was too low to appreciate a decrease in the presence of Tbx1 (Figure 
12A). However, our previous results suggested a putative regulatory 
mechanism of Mef2c expression by Tbx1 that involves Gata4; thus, to 
both confirm this hypothesis and increase basal luciferase activity, assays 
were performed on C2C12 cells transfected with Tbx1 and Gata4 
expression vectors at the same time. As additional control, we performed 
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luciferase assays on C2C12 myoblasts transfected with both Tbx1 and 
Isl1 expression vectors. 
Our results showed again that Tbx1 was able to interfere with Gata4-
dependent luciferase activity enhancement (Figure 12B), but not with the 
Isl1-dependent one (Figure 12C), supporting the hypothesis that Mef2c 
regulation by Tbx1 could be mediated by Gata4 activity, and opening the 
question of whether this regulatory mechanism actually requires Tbx1 
direct binding to the Mef2c  SHF-specific enhancer. 
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Figure 12. Luciferase assays on transfected C2C12 myoblasts. (A) Gata4 and Isl1 
activate the Mef2c SHF-specific enhancer, while Tbx1 doesn’t repress it. Tbx1 
interferes with the Gata4- but not Isl1-dependent activation of the Mef2c SHF 
specific enhancer. 
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3.10 Mef2c regulation by Tbx1 does not require a direct binding to 
the SHF-specific enhancer 
In order to understand if Mef2c regulation requires direct binding of Tbx1 
to the conserved TBE in the SHF-specific enhancer of Mef2c locus, we 
mutagenized three out of ten base pairs within its sequence. 
Luciferase assays were performed on C2C12 cells transfected with the 
mutant (and wt as control) Mef2c-Enh-Luc reporter in the presence of 
both Gata4 and Tbx1, and we found that, also in this case Tbx1 was able 
to interfere with Gata4-dependent Mef2c activation (Figure 13). 
Taken together these results suggest that Mef2c regulation by Tbx1 could 
be mediated by Gata4; this mechanism doesn’t require a direct Tbx1 
binding to the SHF-specific enhancer, so it is likely that Tbx1 can 
somehow interfere with Gata4-dependent Mef2c activation. 
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Figure 13. Luciferase assays on transfected C2C12 myoblasts. Gata4-dependent 
regulation of Mef2c expression by Tbx1 doesn’t require its direct binding to the 
TBE in the SHF-specific enhancer of Mef2c locus. 
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3.11 Tbx1 dosage does not affect Mef2c expression in the absence of 
Gata4 in transfected C1C12 myoblasts 
To test if Tbx1 regulates Mef2c transcription through a mechanism 
involving Gata4, we decided to evaluate Tbx1 dosage-dependent Mef2c 
expression in the absence of Gata4. Since C2C12 myoblasts express 
endogenous Gata4, we used siRNAs specifically direct against the Gata4 
locus in order to compare Mef2c expression level in Tbx1 overexpressing 
myoblasts, where also Gata4 was knocked down, to cells where only 
Gata4 was downregulated by RNA interference. If Tbx1 and Gata4 
independently regulate Mef2c, we expected an increased downregulation 
of the gene when at the same time, Tbx1 was overexpressed and Gata4 
knocked down, since both Tbx1 over-expression and Gata4 
downregulation result in a lower Mef2c level. On the other hand, if Tbx1 
regulates Mef2c expression through a mechanism involving Gata4, cells 
where Tbx1 was overexpressed and Gata4 downregulated, had to show a 
Mef2c dosage comparable to that of cells where only Gata4 was knocked 
down, since in the absence of Gata4 (or with a small residual protein 
level) which supposedly is the mediator of the regulatory mechanism, 
there is no more effect of Tbx1 overexpression on Mef2c level. After 
transfection of C2C12 myoblasts with (50 nM) Gata4-specific siRNAs, 
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Gata4 mRNA and protein levels were measured by qRT-PCR and 
Western Blotting respectively (Figures 14A and B). In these conditions 
we had a downregulation of about 80% of the wild type level for both 
Gata4 mRNA (Figure 14A) and protein (Figure 14B), resulting in a 
Mef2c downregulation of about 20% of the wild type level (Figure 15 A). 
Interestingly we found no significant difference in Mef2c level between 
cells were at the same time, Gata4 was knocked down and Tbx1 over-
expressed, compared to C2C12 myoblasts where only Gata4 was 
downregulated (Figures 15A, B and C). This result strongly supports our 
hypothesis of a Gata4-mediated Mef2c regulation by Tbx1. 
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Figure 14. Endogenous Gata4 RNA interference in C2C12 myoblasts. (A) qRT-PCR 
and (B) Western Blotting analysis on C2C12 myoblast transfceted with Gata4siRNAs 
and non-targeting (NT) siRNAs. CE and NE: cytoplamic and nuclear extracts 
respectively. 
Figure 15. qRT-PCR on mRNA from transfected C2C12 myoblasts. (A) In the 
absence of Gata4, Tbx1 is not still able to regulate Mef2c expression. (B) Gata4 
and (C) Tbx1 mRNA dosage in transfected C2C12 where Mef2c expression level 
was measured.
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3.12 Mef2c is negatively regulated by Tbx1 in skeletal muscle cells in 
vivo 
If Mef2c expression is Tbx1 dosage-dependent in vivo, we expected to 
observe a Mef2c downregulation in Tbx1 gain-of-function mutants. To 
this aim, whole mount in situ hybridization was performed on 
COET;Mesp1Cre/+ embryos at E9.5 (148); the COET (for Conditional 
over-expression of Tbx1) transgene expresses Tbx1 mRNA in response to 
Cre recombination. Mesp1 is initially expressed in epiblast cells sorting 
through the primitive streak and is quickly downregulated after E7 (149), 
i.e. before Tbx1 is turned on. The progeny of Mesp1-expressing cells 
contributes heavily to the cranial mesoderm (149). Mesp1Cre-induced 
recombination, as visualized by crosses with the R26R reporter (233), is 
restricted to mesodermally derived tissues and was not detected in 
endodermal or ectodermal cells. So Mesp1Cre drives Tbx1 expression in 
all its mesodermal domains of the pharynx, head mesenchyme and 
splanchnic mesoderm (Figure 16). 
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COET;Mesp1Cre/+ 
Figure 16. Whole mount in situ hybridization on E9.5 
wt and COET;MespCre/+ mutant embryos with a 
digossigenin-labeled Tbx1 antisense probe. Tbx1 is 
over-expressed in all its mesodermal domains. 
WT 
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A single mix of probe and hybridization solution was used to examine 
E9.5 wild type and mutant embryos in adjacent wells of a six well dish, in 
order to keep experimental conditions as closely similar as possible 
between the two groups of embryos.  
According with our previous data, whole mount ISH showed a Mef2c 
down-regulation in the SHF of COET;Mesp1Cre/+ mutants compared to 
control embryos (Figure 17). 
It has been show that of the four vertebrate Mef2 genes, Mef2c is the 
earliest to be expressed in skeletal muscle (210); in particular Mef2c 
expression, in the mouse should be dectectable, even if very low, by E9.0 
in the myotomal compartment within rostral somites, and expand 
throughout all of skeletal muscle as development progresses (210). In our 
previous in situ hybridization experiments, we were not able to appreciate 
Mef2c expression in somite compartment of wt embryos at E9.5; here 
instead we found a strong Mef2c expression in somites of control 
embryos and, interestingly this expression was dramatically reduced in 
COET;Mesp1Cre/+ (Figure 18), suggesting that Tbx1 is able to repress 
Mef2c also is skeletal muscle cells. 
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Figure 17. Whole mount in situ hybridization on E9.5 wt and 
COET;MespCre/+ mutant embryos with a digossigenin-labeled 
Mef2c antisense probe. Mef2c is down-regulated in the SHF and 
inflow tract of COET;Mesp1Cre/+ mutants. 
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Figure 18. Whole mount in situ hybridization on 
E9.5 wt and COET;MespCre/+ mutant embryos with 
a digossigenin-labeled Mef2c antisense probe. 
Mef2c is down-regulated in the SHF and in somites 
(arrows) of COET;Mesp1Cre/+ mutants.
 106
 
These results open the question of whether Mef2c can be regulated by 
Tbx1, through a Gata4-dependent mechanism, also in skeletal muscle 
cells. 
We analyzed Gata4 expression at E8.5 and E9.5 by whole mount in situ 
hybridization on control and COET;Mesp1Cre/+ mutant embryos. Liao et 
al. (234) previously described a Gata4 ectopic expression in the SHF of 
Tbx1-/- embryos at E9.0-E9.5. So, as expected, we found, a marked Gata4 
downregulation in COET;Mesp1Cre/+ mutant hearts compared to control 
embryos (Figure 19), suggesting that at least partially, Mef2c down-
regulation reflects Gata4 repression by Tbx1. 
Gata4 seems to be not expressed in skeletal muscle cells, so an 
outstanding question is how Tbx1 can negatively regulates Mef2c 
expression in somites. Even if Tbx1 doesn’t bind the putative TBE in the 
SHF-specific enhancer of Mef2c gene, we cannot exclude that it can 
directly bind other regulatory regions, so repressing Mef2c transcription 
in skeletal muscle cells, likely in a tissue-specific manner. Alternatively, 
regulation of Mef2c by Tbx1 could require involvement of an 
intermediate, a skeletal muscle-specific transcription factor which is a 
direct   transcriptional   target  of  Tbx1  or   whose  activity  is  somehow  
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Figure 19. Whole mount in situ hybridization on E8.5 and 
E9.5 wt and COET;MespCre/+ mutant embryos with a 
digossigenin-labeled Gata4 antisense probe. Gata4 is 
down-regulated in the SHF of COET;Mesp1Cre/+ mutants. 
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affected by Tbx1. Good candidates to this role, corresponding to the 
Gata4  one  in  the   cardiac  lineage,  are  basic  helix-loop-helix  (bHLH)  
proteins of MyoD family (235). These transcription factors are required 
for expression of skeletal muscle-specific genes (235-237), including 
Mef2c (235) and seem to be repressed by Tbx1 in our in vitro assays (data 
not shown). 
 3.13 Mef2c is negatively regulate by Tbx1 during in vitro C2C12 
myoblast differentiation 
 C2C12 myoblasts can easily differentiate, in vitro, by switching of 
culture conditions from standard medium supplemented with 10% fetal 
bovine serum (FBS) to medium supplemented with 2% horse serum 
(238). Typically cells form myotubes 3-5 days after culturing in 
differentiation media; however we observed an increased expression of 
myogenic markers like MyoD and myogenin (data not shown) already at 
day 2 of differentiation. 
By qRT-PCR, we also found, as expected, that Mef2c expression 
increases during in vitro C2C12 myoblast differentiation (Figure 20A) 
and interestingly  his  process is  inhibited  by  Tbx1  (Figure 20B). These  
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Figure 20. qRT-PCR on mRNA from differentiating 
C2C12 myoblasts. (A) Mef2c over-expression 
during C2C12 myoblast differentiation. (B) Tbx1 
inhibits Mef2c over-expression during C212 
myoblast differentiation. 
(A) 
(B) 
0
1
0,5 
1,5 
2 
2,5 
1 
1,2 
0,8 
0,6 
0,4 
0,2 
0 
 110
data, together with the observation of a reduced Mef2c expression in 
somite   compartment  of    Tbx1-gain-of-function mutants,   suggest   that  
Tbx1 may also inhibit, in vivo, skeletal muscle cell differentiation 
through a mechanism involving Mef2c transcriptional repression. 
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CHAPTER 4 
Discussion 
22q11DS causes a wide range of congenital abnormalities, and in humans 
is predominantly associated with hemizigosity for approximately 3 Mb of 
DNA, encoding about 40 genes (1). Chromosome engineering, transgenic 
complementation, and gene targeting experiments revealed that 
haploinsufficiency of the T-box transcription factor Tbx1 produces a 
partial phenocopy of the syndrome; Tbx1-/- embryos have a more severe 
spectrum of defects, such as persistant truncus arteriosus, absence of the 
thymus and parathyroid glands, and craniofacial dysmorphism, all 
observed in 22q11DS patients (91-93). Tbx1 acts as transcriptional 
regulator, and thus identification of its downstream targets, will be vital 
in elucidating the developmental pathways affected in 22q11DS. The 
identification of transcription factor targets represents a considerable 
challenge with several techniques having been developed, but no single 
methodology representing the one of choice. Here, we have described a 
microarray-based transcriptome analysis to evaluate gene expression 
changes in vivo, using a novel dosage gradient approach. Pharyngeal and 
heart development is very sensitive to Tbx1 dosage, as we have shown by 
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generation of a panel of mutants expressing a nearly continuous variation 
of Tbx1 mRNA level between 0 and 100% of the wild-type level (239). 
Microarray analysis at E9.5, identified 256 genes differentially expressed 
across the allelic series (120 down-regulated and 136 up-regulated); of 
these, 52 changed in a manner that was highly correlated (or anti-
correlated) to Tbx1 expression. It is likely that genes highly sensitive to 
perturbations in Tbx1 level are linked to fundamental disease-associated 
processes, whereas those that are only moderately affected by Tbx1 
haploinsufficiency perhaps have roles in modulating the severity of the 
22q11DS-associated defects. Modifier genes might therefore be involved 
in modulating Tbx1 expression from the remaining wild-type allele in 
response to haploinsufficiency or may act as genetic amplifiers to 
enhance expression of specific Tbx1 targets. 
Fgf8 and Fgf10 expression is downregulated in Tbx1-/- mice (103, 120); 
but neither gene was expressed above threshold levels in our experiments. 
We also noted some inconsistencies between our microarray data and a 
few previous reports about expression changes of Tbx1-regulated genes 
(234); many of these are down- or up-regulated in a tissue-specific 
manner, while our microarray analysis was performed on mRNA from 
total embryos. A possible explanation of why our analysis failed to detect 
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expression changes of previously reported genes is that Tbx1 target genes 
may also be expressed in non Tbx1-expressing tissues at E9.5; so the 
differential regulation of such targets will be diluted using the methods 
employed here, despite for example dissection of the pharyngeal 
apparatus containing regions. 
We have confirmed the microarray data on a subset of selected genes 
using quantitative real-time PCR of mRNA from mutant embryos and 
also from in vitro gain of function models; in addition bioinformatic 
analysis of the 10 kb immediately upstream and intronic regions revealed, 
in all the confirmed genes, potential conserved Tbx1 binding sites.  
4.1 Pex2 and Vps33a: cytoplasmic organelle biogenesis and brain 
abnormalities 
Behavioral and psychiatric disorders are a prominent part of the 22q11DS 
phenotype. In children, these disorders include cognitive defects, anxiety, 
attention deficit disorder, and problems of social interaction that are 
increasingly recognized to meet the criteria of autistic spectrum disorder 
(240, 241), a neurodevelopmental disorder. In adults, high rates of 
psychotic disorders, especially schizophrenia, have been reported (241-
244). 
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Df1/+ mice which recapitulate many of the cardiovascular defects 
associated with 22q11DS (88), also display abnormal behavior, including 
impaired sensorimotor gating, as measured by prepulse inhibition (PPI) 
of the startle response (90), a behavioral abnormality that is associated 
with several psychiatric and behavioral disorders including schizophrenia 
and schizotypal personality (245), 22q11DS (246), and Asperger 
syndrome (247). We previously demonstrated that PPI deficits in Df1/- 
mice are caused by haploinsufficiency of two genes, Tbx1 and Gnb1l 
(248): mutation of either gene is sufficient to cause reduced PPI. In 
addition, we reported that psychiatric disorders, in particular Asperger 
syndrome, can occur in association with inactivating mutations of TBX1, 
rather than with a 22q11 chromosomal deletion, consistent with our 
mouse studies (248). Tbx1 and Gnb1l are apparently unrelated and have 
distinct expression patterns in brain, suggesting that they are unlikely to 
function in the same genetic pathway. Future studies into the functions of 
these two genes in brain should clarify the genetic pathways affected by 
their mutation and, potentially, may lead to the identification of drug 
targets aimed at prevention and or treatment of the psychiatric symptoms 
in 22q11DS patients. 
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Tbx1 expression is very low in preterm embryonic brain, whereas levels 
increase steadily from birth to 3 months; in addition it seems to be limited 
to the vasculature in term embryos and in adult mice (248). 
Interestingly, among the confirmed genes, there are two genes involved 
in cytoplasmic organelle biogenesis and whose mutations are associated 
with defects in the developing and postnatal brain: Pex2 (154) and 
Vps33a (169, 170). 
In particular, peroxisome biogenesis disorders, of which Zellweger 
syndrome is the most severe, result in severe neurological dysfunction 
associated with abnormal CNS neuronal migrations due to the lack of 
functional peroxisomes (159, 249, 250). The Pex2-/- mouse model for 
Zellweger syndrome has enabled researchers to evaluate the role of 
peroxisomes in the development and functioning of the nervous system. 
These studies have shown that, in addition to disturbances in neuronal 
migration in developing cerebral cortex and cerebellum, defects in 
neuronal differentiation, proliferation and survival may also contribute to 
the CNS malformations (160, 251). 
The peroxisome is a ubiquitous cellular organelle that participates in a 
wide variety of metabolic reactions. In Zellweger syndrome, infants have 
neonatal hypotonia and seizures associated with CNS neuronal migration 
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defects. In the postnatal period, severe hepatic dysfunction ensues, with 
development of fatty liver, cholestasis and cirrhosis. CNS degeneration 
continues, with abnormalities in myelination and astrocyte proliferation. 
The majority of peroxisomal reactions involve lipids, including b-
oxidation and a-oxidation of fatty acids, and synthesis of bile acids, ether 
phospholipids, docosahexaenoic acid and isoprene compounds. In the 
CNS, peroxisomes are generally more abundant in differentiating neurons 
than in mature neurons and are seen at sites such as axon terminals and 
dendrites, where they are rare in the mature nervous system (159, 249, 
250). These findings suggest that peroxisomes are important for neuronal 
cellular enlargement and formation of processes. However, the effect on 
the developing nervous system of the various peroxisomal lipid 
deficiencies as well as potential toxic accumulations (very long-chain 
fatty acids, bile acid, intermediates) has not been established. 
Vps33a, is a member of the Sec1 and Class C multi-protein complex that 
regulates vesicle trafficking to specialized lysosome-related organelles. 
Mutations in Vps33a cause Hermansky–Pudlak Syndrome (HPS)-like-
symptoms in the bf mouse mutant (171). As Sec1 signaling pathways 
have been implicated in pre-synaptic function, Chintala and colleagues 
(252) examined in detail brain size, cerebellar cell number and the 
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behavioral phenotype of bf mutants. Young bf mice exhibited significant 
impairments in several behavioral tests and this defect was augumented 
in older mice confirming a progressive impairment of motor functions 
with age. In addition, general examination of brain sections, did not 
reveal any size difference in the cerebellum of young bf mice when 
compared to their age-matched heterozygous controls; in contrast old bf 
mice, revealed a strong reduction of cerebellar size mostly attributable to 
progressive loss of Purkinje cells (252). 
Our data suggest a putative positive regulation of Pex2 and a putative 
negative regulation of Vps33a by Tbx1; even if these genes belong to the 
Tbx1 dosage-highly correlated group, further analysis is required to 
establish if they are direct transcriptional targets of Tbx1 or if Tbx1 
modulates expression of Pex2 and/or Vps33a transcriptional regulators. 
Mutations in both Pex2 and Vps33a are associated mainly with postnatal 
brain defects and, interestingly, Tbx1 expression in brain increases 
postnatally (248, 253); so it could be interesting to evaluate if Tbx1 
mutants exhibit defects in organelle biogenesis, a study that has not been 
performed so far, and if these defects could cause CNS abnormalities that 
account for some of 22q11DS neurobehavioral phenotypes.  
 
 118
4.2 Morf4l1 and TgfrbIII: positive regulation of cell proliferation 
Our microarray results also revealed differential expression of two genes 
involved in regulation of cell proliferation: Morf4l1 (180) and TgfrbIII 
(181). As expected, by qRT-PCR we found a Morf4l1 (also known as 
Mrg15) downregulation in Tbx1 null mutant embryos while its expression 
was increased in Tbx1-overexpressing cells, suggesting a putative 
positive regulation of Tbx1 on transcription of this gene. Deletion of 
Mrg15 in mice results in death between E14.5 and birth (178); null 
embryos exhibit defects in multiple organs, including heart and are 
approximately 74% the size of their wild-type littermates with most of 
their tissues proportionately smaller, suggesting a role of Mrg15 in 
sustainment of cellular proliferation (178). In particular Mrg15−/– MEFs 
show a significantly increased expression of cell cycle inhibitor p21 
(180). By qRT-PCR we found a p21 upregualtion in Tbx1 null embryos at 
E9.5 (data not shown) suggesting a putative model in which Tbx1 can 
exert its well demonstrated pro-proliferative role through a mechanism 
involving p21 (and may be other cell cycle negative regulators) 
repression: demonstration of p21 overexpression in other tissues than skin 
of Mrg15-/- would suggest a role for Morf4l1 as intermediate in this 
process. 
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On the other hand, by qRT-PCR on mRNA from Tbx1-overexpressing 
cells, we confirmed the microarray–based data of a putative negative 
regulation of TgfrbIII by Tbx1. Binding of transforming growth factors 
beta (TGFb) to their receptors (TbRs) in vivo, is involved in signal 
transduction of many cellular responses including proliferation, 
differentiation, migration and apoptosis (182-186). TbRIII is the most 
abundant TGFb receptor and is traditionally thought to function as a co-
receptor, binding TGFb and presenting it to TbRII (196). However it has 
been demonstrated that TbRIII has an additional role, since it contributes 
to and enhances TGFb-mediated cellular proliferation inhibition through 
both TbRI/Smad3-dependent and p38 mitogen activated protein kinase 
pathways (200), suggesting that Tbx1 can stimulate cell proliferation 
through a mechanism involving TgfrbIII repression. 
While it is possible that these two genes represent direct transcriptional 
targets of Tbx1, additional approaches will be required to address this 
question; anyway negative regulation of TgfrbIII by Tbx1 togheter with 
its positive role on Morf4l1, strongly support our previous data indicating 
a positive effect of Tbx1 on cellular  proliferation in several tissues. 
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4.3 Mef2c: negative regulation of cardiac and skeletal muscle cell 
differentiation 
Our microarray-based transcriptome analysis, also revealed differential 
Mef2c expression across the Tbx1 allelic series; interestingly this gene 
was anti-correlated to Tbx1 dosage. We were able to confirm that result 
by using loss- and gain-of function models, both in vivo and in vitro. 
Particularly, qRT-PCR on mRNA from E9.5 embryos showed a Mef2c 
over-expression in Tbx1-/- mutants compared to their wt littermates; by in 
situ hybridization at the same stage, we were able to appreciate a SHF-
specific up-regulation of Mef2c in Tbx1 null mutant embryos. We also 
observed a Tbx1-dosage dependent Mef2c expression in two independent 
in vitro gain-of-function models: a Tc-inducible Tbx1-overexpressing 
mouse ES cell line and a Tbx1 expression vector-transfected myoblast 
cell line (C2C12); in Tbx1-overexpressing C2C12 cells, we also observed 
a diminished Mef2c protein level. Finally whole mount in situ 
hybridization at E9.5, on COET;Mesp1Cre/+ mutants which over-express 
Tbx1 in all its mesodermal domains of the pharynx, head mesenchyme 
and splanchnic mesoderm, revealed a strong Mef2c down-regulation in 
somite compartment (in addition to the SHF) compared to control 
embryos. 
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Taken together these results strongly supported the hypothesis that Tbx1 
could regulate Mef2c expression in vivo, in both cardiac and skeletal 
muscle cells. But what about the regulatory mechanism? 
Mef2 genes are expressed in cardiac, smooth, and skeletal muscles, 
vasculature, as well as in a restricted set of other tissues (206, 210, 211). 
In particular, targeted inactivation of the Mef2c gene in mice, resulted in 
profound cardiac and vascular defects and embryonic lethality at E9.5 
(214, 254, 255). In Mef2c knockout mice, endothelial cells were initially 
present but failed to organize correctly, suggesting an endothelial cell 
differentiation defect. 
Mef2c is among the earliest markers of the cardiac lineage with 
transcripts evident in the developing heart beginning at about E7.5, 
shortly after the expression of the Nkx2.5 and Gata genes (210, 216-218, 
220-222); of the four vertebrate Mef2 genes, it is the earliest to be 
expressed in skeletal muscle too. However despite the early expression of 
Mef2c in cardiac and skeletal muscle lineages, its activity (and activity of 
other Mef2 genes) is not required for myoblast specification; instead, it 
appears to play a key role in differentiation. This notion is strongly 
supported by work in Drosophila, in which inactivation of the single 
Mef2 gene, results in a complete loss of muscle differentiation in all three 
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muscle lineages, with no apparent defect in myoblast specification (256-
258). 
A common theme that has emerged through the analysis of muscle gene 
transcription is the modularity of cis-regulatory elements, in which 
multiple independent regulatory regions, are required to generate the 
complete spatio-temporal expression pattern of a gene through 
development (259). Accordingly, the proposed model for Mef2c gene 
regulation, is based on the independent regulation of multiple, tissue-
specific, enhancers. In particular De Val et al. identified a transcriptional 
enhancer from the mouse Mef2c gene sufficient to direct its expression to 
the vascular endothelium in transgenic embryos. This enhancer is active 
in endothelial cells within the developing vascular system from very early 
stages in vasculogenesis, and remains robustly active in the vascular 
endothelium during embryogenesis and in adulthood. This Mef2c 
endothelial cell enhancer contains four perfect consensus sites for Ets 
family of winged helix transcription factors; these sites are efficiently 
bound by Ets-1 protein in vitro and are required for enhancer function in 
transgenic embryos (223). They also identified additional, separate, 
modular enhancers from Mef2c that independently direct its expression to 
smooth muscle and to neural crest (unpublished observations). 
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Skeletal muscle development is controlled by the MyoD family of 
myogenic bHLH protiens and MEF2 family of transcription factors, 
which interact to establish a unique transcriptional code for activation of 
skeletal muscle-specific genes (260, 261). Members of the MyoD family 
(MyoD, myogenin, Myf5 and MRF4) are expressed exclusively in the 
skeletal muscle lineage and can each activate the complete muscle 
differentiation program in transfected fibroblasts (262-265). 
Dodou et al. (235) have isolated an enhancer region from the mouse 
Mef2c gene that is sufficient to direct its expression to skeletal muscle 
during murine development; furthermore, they have defined cis-acting 
sequences within the skeletal muscle enhancer of Mef2c that are essential 
for its expression in vivo. Among these cis-acting elements is an E box 
that is bound by myogenic bHLH proteins with extremely high affinity 
and is absolutely required for expression in vivo. The data they presented 
support a direct link between myogenic specification and differentiation, 
by demonstrating that myogenic bHLH proteins directly activate the 
expression of Mef2c in skeletal muscle in vivo. 
Additionally, as mentioned before, Dodou et al. (2) also identified a 
Mef2c SHF-specific enhancer carrying evolutionarily conserved binding 
sites for Gata4 and Isl1 transcription factors; these sites are completely 
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required for enhancer function in vivo. Finally von Both et al. (266) 
demonstrated that Mef2c expression in the SHF is also dependent on 
forkhead transcription factor Foxh1 and identified a Foxh1-Nkx2.5 
binding site within the Mef2c gene, that is regulated by TGFb signalling 
in a Smad-dependent manner.  
The evolution of multiple independent enhancers provides a potential 
mechanism for regulatory diversity by allowing gene expression to be 
controlled in a very fine-tuned manner in each lineage where Mef2c is 
expressed. Another emerging theme is dependence of these tissue- 
specific enhancer, for their functionality, on the combined activities of 
different transcription factor families. 
Accordingly, our results suggest that Mef2c could be regulated by Tbx1 
through different mechanisms between the cardiac and skeletal muscle 
lineages. In particular, our in vitro data, support the hypothesis of a Mef2c 
negative regulation by Tbx1 that is Gata4-dependent. We observed, in 
fact that Tbx1 was able to repress the SHF-enhancer described by Dodou 
et al. (2), only in the presence of  Gata4; this repression does not require a 
Tbx1 direct binding to the conserved TBE we identified in the same 
enhancer. 
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In addition, we observed, by qRT-PCR on mRNA from transfected 
C2C12 myoblasts, that when the 80% of endogenous Gata4 is knocked-
down by RNA interference, Tbx1 over-expression does not still affect 
endogenous Mef2c gene expression, so confirming our hypothesis. 
However, we and other observed that Gata4 is negatively regulated, in 
vivo, by Tbx1; in particular Liao et al. (234) described a Gata4 ectopic 
expression in the SHF of Tbx1-/- embryos at E9.0-E9.5. At the same 
stages, we observed a marked Gata4 downregulation in COET;Mesp1Cre/+ 
gain-of-function mutant hearts compared to control embryos, suggesting 
that at least partially, Mef2c down-regulation reflects Gata4 repression by 
Txb1. 
Gata4, however, is not expressed in skeletal muscle, opening the question 
of how Mef2c is regulated by Tbx1 in that tissue. 
Even if, we did not identify any putative Tbx1 binding site in the skeletal 
muscle-specific enhancer described by Dodou et al. (235), we cannot 
exclude the existence of other regulatory regions that specifically drive 
Mef2c expression in skeletal muscle cells and that are directly bound by 
Tbx1 in vivo. In addition, we can also hypothesize a regulatory 
mechanism similar to that evocated for cardiac lineage, requiring 
involvement of an intermediate transcription factor.  
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Our unpublished data, show a MyoD and myogenin down-regulation in 
Tbx1 over-expressing C2C12 myoblasts, suggesting that these bHLH 
proteins could have, in skeletal muscle cells, a role similar to that 
hypothesized for Gata4, in cardiac lineage. 
Whatever the regulatory mechanism can be, what is the functional 
meaning of Mef2c repression by Tbx1? 
We have recently shown that Tbx1 is expressed in cardiac progenitor cells 
(CPCs) that, in clonal assays, can give rise to the three heart lineages 
expressing endothelial, smooth muscle and cardiomyocyte markers (147). 
In these multipotent cells, Tbx1 stimulates proliferation, explaining why 
Tbx1-/- embryos have reduced proliferation in the SHF. In this population, 
Tbx1 is expressed while cells are undifferentiated and it disappears with 
the onset of muscle markers; loss of Tbx1 is associated with premature 
differentiation, while its ectopic expression in the OFT results in 
suppression of differentiation. Because Tbx1 can regulate Fgf8 
expression in the mesodermal region that includes the SHF (97, 103, 120, 
143, 267), some of its mitogenic activity could be mediated by the FGF 
signaling. On the other hand, Tbx1 seems to inhibit differentiation by 
regulating, directly or indirectly, proteasome-mediated degradation of the 
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myogenic transcription factor Srf which, in turn, activates the muscle 
transcription program.  
So Tbx1 could exert its, in vivo, anti-differentiative role in the SHF 
population of heart progenitors, also repressing Mef2c expression. 
And even if we observed a Gata4 negative regulation by Tbx1, that can 
account for some of in vivo Mef2c down-regulation, our data suggest that 
the mechanism by which Tbx1 regulates Mef2c somehow affects Gata4 
protein activity. So it is possible that regulation of proteosome-mediated 
degradation observed for Srf, is a general mechanism; co-
immunoprecipitation experiments will tell us if Tbx1 can bind, in vivo, 
Gata4 protein and reduce its stability. 
As said above, we also found a Mef2c-downregulation in somite 
compartment of Tbx1-gain-of function mutant embryos and our in vitro 
experiments showed that Mef2c over-expression during C2C12 myoblast 
differentiation is inhibited by Tbx1, suggesting that Tbx1 can negatively 
regulates Mef2c expression in skeletal muscle cells too. Additional 
experiments will clarify if Tbx1 directly binds skeletal muscle-specific 
regulatory regions of Mef2c locus, or, also in this case, Tbx1 interferes 
with the activity of Mef2c direct regulators, for example the myogenic 
proteins of MyoD family. 
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Finally our data beg the question of whether the function of Tbx1 in 
regulating the balance between proliferation and differentiation, may also 
apply to other tissues where Tbx1 is expressed. Indeed, Tbx1 loss of 
function in mice, and, to a lesser extent, TBX1 haploinsufficency in 
DiGeorge syndrome patients, is associated with hypoplasia or aplasia of 
several organs and tissues. Thus, it is tempting to speculate that 
disregulation of the balance between proliferation and differentiation of 
different types of progenitor cells or stem cells may be a basic pathogenic 
mechanism for the loss of function phenotype.  
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CHAPTER 5 
Appendix 
5.1 Towards a human model of DiGeorge Syndrome (DGS) 
Syndromes associated with segmental aneuploidies are caused by gene 
dosage imbalance. There may be one or more critical genes within the 
aneuploid segment, that encode different classes of proteins, but the 
common characteristic is that the processes in which they are involved 
(developmental or otherwise) are sensitive to their concentration. In most 
if not all cases, the mechanisms underlying dosage sensitivity are 
unknown. A complicating issue is that mouse modelling of these 
syndromes, while technically feasible in many cases, is hindered by 
different sensitivity to dosage of a particular gene product across species. 
This problem translates into the finding that similar gene dosage 
reduction in mice and humans (e.g. heterozygous deletion), leads to 
different phenotypes in the two species. Heterozygous multigene deletion 
of region corresponding to 22q11 in the mouse as well as Tbx1+/-  
animals, presented with a less severe phenotype than the majority of 
22q11.2DS patients or TBX1 mutant patients, with the caveat that mild 
patients may escape clinical diagnosis. Most intriguingly, the great 
phenotypic variability observed in human patients could not be modelled 
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in mice, although different phenotypic penetrance, but not expressivity, 
has been reported as a function of strain or genotype at interacting loci 
(89, 91, 103, 268, 269). 
So, murine models of congenital and acquired disease are invaluable yet 
often do not faithfully mirror human pathophysiology; for cases where 
murine and human physiology differ, however, human Embryonic Stem 
cell (hESc) culture represents an essential complement to research with 
animal models. 
ES cells, derived from the inner cell mass of mammalian blastocysts, 
have the ability to grow indefinitely while maintaining pluripotency (270, 
271), and allow investigators to explore early stages of human embryonic 
development through in vitro differentiation, which ricapitulates aspects 
of normal gastrulation and tissue formation. So in vitro differentiating 
genetically modified ES cells, are particularly attractive for the study of 
congenital disorders, offering the unprecedented opportunity to study in 
detail disease initiation and progression during development, moreover 
enabling generation of customized cellular therapies by in vitro gene 
correction in autologous cells. Use of human embryos, however, faces 
ethical controversies that hinder the applications of human ES cells; in 
addition it is difficult to generate patient-or-disease specific ES cells, 
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which are required for their effective application. One strategy for 
producing autologous, patient-derived pluripotent stem cells is somatic 
nuclear transfer (NT); in a proof of principle experiment, NT-ES cells 
generated from mice with genetic immunodeficiency were used to 
combine gene and cell therapy to repair the genetic defect (272). To date, 
NT has not proven successful in the human, and given the paucity of 
human oocytes, is destined to have limited utility; in contrast, introducing 
a set of transcription factors linked to pluripotency can directly reprogram 
human somatic cells to produce induced pluripotent stem (iPS) cells, a 
method that has been achieved by several groups worldwide (273-276). 
Reprogramming somatic cells taken from patients with specific diseases, 
can truly turn back time in patient’s history, allowing the unique 
opportunity to study disease development in the specific context of each 
individual. Since successfully generation of disease-specific pluripotent 
stem cell lines by reprogramming of patient skin or blood samples (277-
283), has been recently reported, we tried to reprogram adult fibroblasts 
from a DiGeorge syndrome patient, by transduction of a set of five genes 
encoding the transcription factors OCT4, SOX2, C-MYC, KLF4 and 
NANOG, as described by Lowry et al. (274). To date we obtained a 
promising clone, that we are still characterizing; however, our 
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preliminary results, open the possibility to obtain DGS-specific 
pluripotent stem cells as the starting materials for generating an in vitro 
model of the human disease, improving our understanding of its initiation 
and progression during development as well as our knowledge of Tbx1 
role in its pathogenesis. 
5.2 Materials and Methods 
5.2.1 Cell culture 
Retroviral pMX vectors encoding OCT4, SOX2, C-MYC, NANOG, KLF4, 
and GFP (Addgene) were transfected into Phoenix Ampho Cells 
(Orbigen) by using Fugene (Roche). Viral supernatants were harvested 3 
days later, combined, and used to infect DiGeorge syndrome fibroblasts 
(GM07215, Coriell Institute) in DMEM with 10% FBS (Foundation), 
nonessential amino acids, L-glutamine, and penicillin–streptomycin 
(Invitrogen). A second round of infection was performed at day 3, and the 
transfection efficiency of each virus as extrapolated from that of GFP in 
the viral mix was 15–20%, suggesting that nearly 100% of cells received 
at least one virus. Four days later, cells were passaged onto irradiated 
murine embryonic fibroblasts (MEFs). Reprogrammed cells and hES 
cells (H9) were cultured on irradiated MEFs as described (284, 285) in 
DMEM F12 supplemented with L-glutamine, nonessential amino acids, 
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penicillin–streptomycin, knockout serum replacement (Invitrogen), and 4 
ng/ml basic FGF. For early passages, iPS cells were propagated 
manually, whereas subsequent passaging was performed with collagenase 
treatment as described (284, 285).  
5.2.2 Genomic DNA analysis 
Genomic DNA was isolated by using the DNeasy kit (Qiagen) and 
analyzed for retroviral integration events by PCR with specific primers 
(273). 
5.2.3 Expression analysis 
Total RNA was isolated by using the RNeasy Mini Kit (QIAGEN) and 
reverse-transcribed with the ImProm-II Reverse Transcription System 
(Promega) with oligo dT primers. cDNAs was analyzed by PCR with 
specific primers (273). 
5.2.4 Alkaline Phosphatase Staining, Immunofluorescence and DAPI 
staining 
Alkaline phosphatase staining was performed using the Alkaline 
Phosphatase Substrate Kit III (Vector Laboratories) according to the 
manufacturer’s instructions. 
For immunoflorescence, cells were fixed with PBS containing 2% 
paraformaldehyde (EMS) for 1 hour at room temperature. After washing 
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with PBS, the cells were treated with PBS containing 2% FBS 
(Foundation), 0,1% sodium azide (Sigma-Aldrich), for 30 minutes at 
room temperature. For OCT3/4 staining cells were permeabilized with 
cold 90% methanol (Sigma Aldrich) for 30 minutes at 4°C. Primary 
antibodies included: monoclonal Oct-4 (Santa Cruz Biotechnology, 
1:200), monoclonal SSEA-4 (Santa Cruz Biotechnology, 1:200), IgG2b 
(Santa Cruz Biotechnology, 1:200) and IgG3 (Santa Cruz Biotechnology, 
1:200). Primary antibodies were diluted in PBS containing 2% FBS 
(Foundation), 0,1% sodium azide (Sigma-Aldrich) and 0,1% Triton-100 
(Sigma Aldrich). Secondary antibodies used were: goat anti-mouse IgG-
FITC (Santa Cruz Biotechnology, 1:1000) and Alexa Fluor 488 goat anti-
mouse IgG (Invitrogen, 1:1000). Secondary antibodies were diluted in 
PBS containing 2% FBS (Foundation), 0,5% sodium azide (Sigma-
Aldrich) and 0,1% Triton-100 (Sigma Aldrich). 
For DAPI (4’-6-Diamidino-2-phenylindole) staining, OCT3/4 and SSEA-
4 labeled cells, were washed with PBS containing 2% FBS (Foundation), 
0,1% sodium azide (Sigma-Aldrich) and 0,1% Triton-100 (Sigma 
Aldrich) and treated with PBS containing 1ug/ml DAPI (Invitrogen) for 1 
minute at room temperature. 
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5.2.5 Fluorescence-activated cell sorting analysis 
For Fluorescence-activated cell sorting (FACS) analysis, 2.5 x 106cells 
were resuspended in 0.5 ml of PBS containing 2% FBS (Foundation) and 
0,1% sodium azide (Sigma-Aldrich) and divided into five 0.1 ml aliquots 
(aliquot 1: negative control, aliquot 2: CD-29 labeling to exclude the 
MEF feeder cell population, aliquot 3: OCT3/4 labeling, aliquot 4 SSEA-
4 labeling, aliquot 5: OCT3/4 and SSEA-4 double labeling). Aliquot 1 
was labeled with IgG1 antibody (Alexa 488, AbD Serotec); aliquot 2 was 
labeled with CD-29 antibody (Alexa 488, AbD Serotec); aliquot 3 was 
labeled with SSEA-4 (R&D Systems) and IgG1 antibodies; aliquot 5 was 
labelled with CD-29 and SSEA-4 antibodies (0.01 ml of each antibody, 
for 30 minutes at 4°C.) 
Cells were then fixed with PBS containing 2% paraformaldehyde (EMS) 
for 30 minutes at room temperature and permeabilized with PBS 
containing 0,1% Bovine Serum Albumin (Sigma Aldrich) and 0,1% 
Saponine (Sigma Aldrich). After centrifugation, each aliquot was 
resuspended  in about 0.05 ml of permeabilization buffer and 0.01 ml of 
the following antibodies were added: IgG1 (PE, BD Biosciences for 
aliquots 1, 2 and 4), Oct-4 (PE, BD Biosciences for aliquots 3 and 5). 
Cells from each aliquot were also stained with PBS containing 1ug/ml 
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DAPI (Invitrogen), transfered to FACS tubes using cell strainers (BD 
Biosciences) and stored at least 1 hour at 4°C. FACS analysis was 
performed using a LSR II (BD Biosciences). 
5.3 Results and discussion 
5.3.1 Generation of human induced Pluripotent Stem (hiPS) cells 
from DGS fibroblasts 
Human  foreskin fibroblasts donated from a single newborn DGS patient 
(referred as DGSF), were reprogrammed to an ES-like state, by retroviral 
transduction of a set of five genes encoding the transcription factors 
NANOG, OCT3/4, SOX2, C-MYC and KLF4 as described by Lowry et 
al. (274). 
After virus generation in Phoenix-A packaging cells using pMX vectors 
encoding the five factors, fibrobalsts were infected twice over 3 days and 
replated four days later onto a feeder layer of irradiated murine 
embryonic fibroblasts (MEFs); a GFP-expressing pMX virus was added 
to monitor infection efficiency. Control cells infected with empty pMX 
virus and the GFP-bearing virus in a 5:1 ratio did not change the 
morphology of the cells, which continued to grow as a monolayer. In 
contrast, in those fibroblasts cultures that were infected with viruses 
carrying the five defined factors and GFP, colonies formed about two 
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weeks after infection; these “early” colonies, however, didn’t show a 
hESc-like morphlogy, with characteristic refractive edges and three-
dimensional growth. At three weeks after infection, a new colony 
emerged in the infected fibroblast cultures that adopted a tightly packed 
morphology, reminiscent of hESc colonies. Since, as described, it could 
have been reprogrammed to an ES-like state, this “late” appearing colony 
was picked from the original plate and expanded. Since the original clone 
(namely clone #18), after few passages, started to adopt a heterogeneous 
morphology, we derived from it three more subclones (namely #18.1, 
18.6, 18.9). Colonies from these three subclones were cultured in hESc 
media (with knockout serum replacer and basic FGF) on irradiated MEFs 
and were propagated with standard protocols using collagenase (Amit et 
al.2006 Methods Mol Biol; Akutsu et al. 2006 Methods Enzymol); since 
after several passages in culture, these colonies were still showing an 
hESc-like morphology (Figure 21) we decided subsequently, to analyze 
them in more detail to understand whether faithfully reprogramming to 
the ES-like state, had indeed occurred. 
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Subclone 18.1 
Subclone 18.9 
Figure 21. Morphology of colonies from subclones 18.1, 18.6 and 18.9. 
Subclone 18.6 
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5.3.2 Characterization of hiPS cells generated from DGS fibroblasts 
5.3.2.I Alkaline Phosphatase staining 
Alkaline Phosphatase (AP or TRA-2-49/6E) is a hydrolase responsible 
for dephosphorylating molecules such as nucleotides, proteins, and 
alkaloids, under alkaline conditions. It is a stem cell membrane marker 
and high levels of expression of this enzyme are typically associated with 
the undifferentiated state of pluripotent cells (286). 
Colonies from our original clone and all tested subclones showed positive 
staining for alkaline phosphatase (Figure 22), suggesting that they could 
effectively be the result of efficient reprogramming of DGS fibroblasts to 
an ES-like status.   
5.3.2.II Genotype analysis 
PCR on genomic DNA revealed integration of all the five retroviruses 
used for DGS fibroblast reprogramming in all tested subclones (Figure  
23).  
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18.1 18.6 Mock Clone 18 
pMX OCT3/4 
pMX SOX2 
pMX NANOG 
pMX C-MYC 
pMX KLF4 
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Figure 23. Genomic PCR revealing integration of all the five retroviruses in 
subclones 18.1,18.6 and 18.9. 
Figure 22. AP staining of (A) the original clone and (B) subclones 18.1, 18.6 and 
18.9. 
18.9 
(A) 
Subclones
(B) 
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5.3.2.III ES cell marker expression analysis 
RT-PCR showed that our original clone and all subclones express the 
endogenous counterparts of the defined factors using for reprogramming 
(endogenous OCT3/4, SOX2, NANOG, C-MYC and KLF4) as well as 
many un-differentiated ES cell-marker genes (286) such as reduced 
expression 1 (REX1),  developmental pluripotency-associated 2 
(DPPA2), DPPA4, DPPA5 growth and differentiation factor 3 (GDF3), 
fibroblast growth factor4 (Fgf4), msh homeobox 1 (MSX1) and 
telomerase reverse transcriptase (TERT) at levels equivalent to those in 
the hES cell line H9 (Figure 24). 
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Figure 24. RT-PCR showing expression of endogenous OCT3/4, 
SOX2, NANOG, C-MYC, KLF4 and several human embryonic stem 
cell marker genes. 
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5.3.2.IV OCT3/4 expression analysis 
Since a critical level of Oct3/4 is required to maintain the pluripotency 
and self-renewal of ES cells (287, 288), we also tested our subclones for 
OCT3/4 protein expression, by immunofluorescence. As confirmed by 
DAPI staining, in each colony, all cell nuclei were strongly positive for 
OCT3/4 (Figure 25). 
5.3.2.V SSEA-4 surface antigen expression analysis 
Another approach to defining and characterizing stem cells, perhaps the 
most versatile, is that based upon the surface antigen phenotype of the 
cells (286). The extracellular markers that have been used to characterize 
hES cells are primarily carbohydrate epitopes on proteoglycans or 
sphingolipids, such as stage-specific embryonic antigen (SSEA)-3 and -4 
(286, 289, 290). 
Also several glycoproteins are specifically expressed by hES cells 
including Thy1, the major histocompatibility complex (MHC) class 1 
antigens (HLA), a series of tumor related antigens, notably the keratin 
sulfate proteoglycans TRA-1-60, TRA-1-81, and GCTM2 (291, 292). As 
a starting point, we tested our subclones for SSEA-4 expression, by 
immunofluorescence, and found that all of them stained homogenously 
positive for this surface antigen (Figure 26). 
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Subclone 18.1 
Subclone 18.6 
Subclone 18.9
Figure 25. Immunofluorescence analysis revealing OCT3/4 expression in subclones 
18.1, 18.6 and 18.9. 
OCT3/4 DAPI MERGE
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SSEA-4 DAPI MERGE 
18.6 
18.9 
Figure 26. Immunofluorescence analysis revealing SSEA-4 expression in 
subclones 18.1,18.6 and 18.9.
18.1 
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5.3.2.VI Fluorescence-activated cell sorting analysis  
To quantitatively evaluate OCT3/4 and SSEA-4 expression observed in 
our subclones, we also performed a fluorescence-activated cell sorting 
(FACS) analysis. In a homogeneous hES cell population, tipically the 
80% of cells express at the same time OCT3/4 and SSEA-4 (data not 
shown). We found a 82% of double positive cells in our subclone 18.1, a 
93% in subclone 18.6 and a 97% in subclone 18.9 respectively (Figure 
27). 
To demonstrate the pluripotency of our subclones, we need to confirm 
their ability to both form teratomas in immunodeficient (SCID) mice and 
differentiate in vitro in multiple lineages.  
To exclude the possibility that our hiPS cells are simply a contaminant 
from laboratory hES cell cultures, DNA fingerprinting will be used to 
accurately identify their origin. In addition kariotypic analysis will be 
required to show that gross chromosomal abnormalities were not 
generated as a result of reprogramming, so suggesting that large genomic 
rearrangements are not required for reprogramming to occur. 
And even if multiple iPS cell lines made from a single patient should be 
genetically identical, it remains possible that these will display functional 
differences  as  a  result  of  epigenetic  drift  between  clones;  so  several  
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Figure 27. FACS analysis showing the percentage of OCT3/4-SSEA-4 double positive 
cells in subclones 18.1, 18.6 and 18.9.
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clones should be studied  from  the same  patient,  requiring  us  to  obtain  
additional iPS cell lines from the same patient fibroblast donor. 
5.3.3 Human induced Pluripotent Stem cells and disease modeling 
Many transgenic murine models of congenital and acquired diseases do 
not faithfully mirror the respective human pathophysiology; differences 
in tissue composition, anatomy, and physiology between animals and 
humans, all may underlie these observations. Another challenge in using 
murine disease models can arise from the differences in colinearity of the 
human and mouse genomes and the lack of conservation of gene order; so 
the same genetic abnormalities often do not produce identical 
phenotypical defects in the two species. Further, only a relatively small 
subset of age-regulated gene expression changes, is conserved from 
mouse to man. Lastly, the inbred genetic background of mice can also 
influence the phenotype resulting from the disease-associated mutations. 
Humans are of mixed genetic background, and this complexity results in 
phenotypical variations of genetically defined diseases. So although 
animal models continue to produce key insights into disease mechanisms, 
these systems have limitations that could be potentially overcome by 
human cellular models of disease. 
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For cases where murine and human physiology differ, so disease-specific 
pluripotent cells capable of differentiation into the various tissues 
affected in each condition, could undoubtedly provide new insights into 
disease pathophysiology by permitting analysis in a human system, under 
controlled conditions in vitro, using a large number of genetically-
modifiable cells, and in a manner specific to the genetic lesions in each, 
whether known or not. 
Our preliminary results open the possibility to generate induced 
pluripotent stem cells as starting material to develop a human model of 
DiGeorge syndrome. 
The establishment of disease models through patient-specific 
reprogramming involves two steps: first, derivation of hiPS cells from 
somatic cells of a patient and second, differentiating the established hiPS 
clones into cell types affected by the patient’s disease. 
Successfully generation of disease-specific Pluripotent Stem cell lines by 
reprogramming of patient skin or blood samples (277-283) has been 
described; however, so far, only a handful of reports have observed a 
disease phenotype in vitro (279, 282, 293, 294). 
During mouse cardiogenesis, the major lineages of the mature heart, 
cardiomyocytes, smooth muscle cells, and endothelial cells arise from a 
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common, multipotent cardiovascular progenitor expressing the 
transcription factors Isl1 and Nkx2.5 (295-297). 
We have recently reported that Tbx1 marks these multipotent cells, 
supports their proliferation and inhibits their differentiation (147). 
Interestingly, Moretti et al. have (298) recently shown that Isl1+ 
multipotent cardiovascular progenitors, can be generated from mouse iPS 
cells and spontaneously differentiate in all three cardiovascular 
progenitors in vivo. 
They also reported the identification of human iPS-derived ISL1+ 
progenitors with similar developmental potential; it will be interesting to 
test if TBX1 is expressed in cardiac progenitor cells also in humans. 
Most disease phenotypes are only observed in lineage-committed or 
differentiated cells and not in the ES cells or iPS cells, so pertinent 
information on the pathogenesis of a disease may only be obtained from 
hiPS cells that have been differentiated in vitro to disease-relevant cell 
types. In addition, the specificity of a particular disease phenotype should 
be checked by direct or indirect correction of the genetic lesion. 
Since Tbx1 regulates the balance between proliferation and 
differentiation in cardiac progenitor cells, it will be interesting to apply 
the protocol described by Moretti et al. (298) to the hiPS cells derived 
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from DGS fibroblasts to observe a possible disease phenotype; and if this 
will be the case, the rescue of the observed phenotype by TBX1 
transduction, will allow us to better understand the molecular mechanism 
underlying TBX1 function on a cellular level. 
Hypoplasia or aplasia of several organs and tissues is observed in TBX1 
mutant patients. Since hiPS cells can differentiate in vitro, in multiple 
lineages, availability of an in vitro cellular model of DGS, will help us in 
understanding whether disregulation of the balance between proliferation 
and differentiation of different types of progenitors cells or stem cells, 
may be a key molecular mechanism underlying the disease pathogenesis. 
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